[10-Q] TELEFLEX INC Quarterly Earnings Report

Rhea-AI Filing Summary

Teleflex (TFX) reported a sharp swing to loss on non-cash charges. For the quarter ended September 28, 2025, net revenues were $913,021, up from $764,375 a year ago, reflecting contributions from the newly acquired Vascular Intervention business. However, the company posted a net loss of $(408,892), driven primarily by a $403,925 goodwill impairment in Interventional Urology and a $100,000 impairment tied to Titan SGS.

Operating trends were mixed: gross profit rose to $451,642, but higher SG&A and R&D, plus restructuring and separation costs, pressured results. Year‑to‑date, revenue reached $2,394,579 while net loss was $(191,310). Teleflex closed the BIOTRONIK Vascular Intervention acquisition for €704.3 million ($825.2 million) and financed it with a $700 million delayed draw term loan and additional revolver borrowings. Total borrowings increased to $2,681,250, and cash from operations was $188,971 year‑to‑date as investing cash outflows reflected the acquisition.

The company is advancing plans to separate NewCo, with $32,144 in year‑to‑date separation costs. Shares outstanding were 44,194,408 as of November 4, 2025.

Insights

Equity analyst — medical devices

Impairments drove a large GAAP loss despite strong revenue.

Teleflex delivered solid top-line growth with Q3 net revenues of $913,021, aided by the VI Business. The quarter’s GAAP loss of $(408,892) was dominated by a $403,925 goodwill impairment in Interventional Urology and a $100,000 Titan SGS asset impairment, alongside restructuring and separation costs.

The VI acquisition closed at $825.2M, funded by a $700M delayed draw term loan and revolver usage, lifting total borrowings to $2,681,250. Cash from operations was $188,971 year‑to‑date, while investing outflows reflected deal funding. Hedging gains supported SG&A earlier in the year.

Key dependencies include integration of the VI Business, stabilization of Interventional Urology demand, and execution on the potential NewCo separation. Subsequent filings may detail progress on purchase accounting adjustments and ongoing separation costs.

false2025Q30000096943--12-31xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiso4217:EURtfx:agreementtfx:counterpartyiso4217:CHFtfx:segment00000969432025-01-012025-09-2800000969432025-11-0400000969432025-06-302025-09-2800000969432024-07-012024-09-2900000969432024-01-012024-09-2900000969432025-09-2800000969432024-12-3100000969432023-12-3100000969432024-09-290000096943us-gaap:CommonStockMember2024-12-310000096943us-gaap:AdditionalPaidInCapitalMember2024-12-310000096943us-gaap:RetainedEarningsMember2024-12-310000096943us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000096943us-gaap:TreasuryStockCommonMember2024-12-310000096943us-gaap:RetainedEarningsMember2025-01-012025-03-3000000969432025-01-012025-03-300000096943us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-300000096943us-gaap:CommonStockMember2025-01-012025-03-300000096943us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-300000096943us-gaap:TreasuryStockCommonMember2025-01-012025-03-300000096943us-gaap:CommonStockMember2025-03-300000096943us-gaap:AdditionalPaidInCapitalMember2025-03-300000096943us-gaap:RetainedEarningsMember2025-03-300000096943us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-300000096943us-gaap:TreasuryStockCommonMember2025-03-3000000969432025-03-300000096943us-gaap:RetainedEarningsMember2025-03-312025-06-2900000969432025-03-312025-06-290000096943us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-312025-06-290000096943us-gaap:CommonStockMember2025-03-312025-06-290000096943us-gaap:AdditionalPaidInCapitalMember2025-03-312025-06-290000096943us-gaap:TreasuryStockCommonMember2025-03-312025-06-290000096943us-gaap:CommonStockMember2025-06-290000096943us-gaap:AdditionalPaidInCapitalMember2025-06-290000096943us-gaap:RetainedEarningsMember2025-06-290000096943us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-290000096943us-gaap:TreasuryStockCommonMember2025-06-2900000969432025-06-290000096943us-gaap:RetainedEarningsMember2025-06-302025-09-280000096943us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-302025-09-280000096943us-gaap:CommonStockMember2025-06-302025-09-280000096943us-gaap:AdditionalPaidInCapitalMember2025-06-302025-09-280000096943us-gaap:TreasuryStockCommonMember2025-06-302025-09-280000096943us-gaap:CommonStockMember2025-09-280000096943us-gaap:AdditionalPaidInCapitalMember2025-09-280000096943us-gaap:RetainedEarningsMember2025-09-280000096943us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-280000096943us-gaap:TreasuryStockCommonMember2025-09-280000096943us-gaap:CommonStockMember2023-12-310000096943us-gaap:AdditionalPaidInCapitalMember2023-12-310000096943us-gaap:RetainedEarningsMember2023-12-310000096943us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000096943us-gaap:TreasuryStockCommonMember2023-12-310000096943us-gaap:RetainedEarningsMember2024-01-012024-03-3100000969432024-01-012024-03-310000096943us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000096943us-gaap:CommonStockMember2024-01-012024-03-310000096943us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000096943us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000096943us-gaap:CommonStockMember2024-03-310000096943us-gaap:AdditionalPaidInCapitalMember2024-03-310000096943us-gaap:RetainedEarningsMember2024-03-310000096943us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000096943us-gaap:TreasuryStockCommonMember2024-03-3100000969432024-03-310000096943us-gaap:RetainedEarningsMember2024-04-012024-06-3000000969432024-04-012024-06-300000096943us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000096943us-gaap:CommonStockMember2024-04-012024-06-300000096943us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000096943us-gaap:TreasuryStockCommonMember2024-04-012024-06-300000096943us-gaap:CommonStockMember2024-06-300000096943us-gaap:AdditionalPaidInCapitalMember2024-06-300000096943us-gaap:RetainedEarningsMember2024-06-300000096943us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000096943us-gaap:TreasuryStockCommonMember2024-06-3000000969432024-06-300000096943us-gaap:RetainedEarningsMember2024-07-012024-09-290000096943us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-290000096943us-gaap:CommonStockMember2024-07-012024-09-290000096943us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-290000096943us-gaap:TreasuryStockCommonMember2024-07-012024-09-290000096943us-gaap:CommonStockMember2024-09-290000096943us-gaap:AdditionalPaidInCapitalMember2024-09-290000096943us-gaap:RetainedEarningsMember2024-09-290000096943us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-290000096943us-gaap:TreasuryStockCommonMember2024-09-290000096943tfx:HospitalsAndHealthcareProvidersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-09-280000096943tfx:OtherMedicalDeviceManufacturersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-09-280000096943tfx:HomeCareProvidersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-09-280000096943tfx:VascularAccessMember2025-06-302025-09-280000096943tfx:VascularAccessMember2024-07-012024-09-290000096943tfx:VascularAccessMember2025-01-012025-09-280000096943tfx:VascularAccessMember2024-01-012024-09-290000096943tfx:InterventionalMember2025-06-302025-09-280000096943tfx:InterventionalMember2024-07-012024-09-290000096943tfx:InterventionalMember2025-01-012025-09-280000096943tfx:InterventionalMember2024-01-012024-09-290000096943tfx:AnesthesiaMember2025-06-302025-09-280000096943tfx:AnesthesiaMember2024-07-012024-09-290000096943tfx:AnesthesiaMember2025-01-012025-09-280000096943tfx:AnesthesiaMember2024-01-012024-09-290000096943tfx:SurgicalMember2025-06-302025-09-280000096943tfx:SurgicalMember2024-07-012024-09-290000096943tfx:SurgicalMember2025-01-012025-09-280000096943tfx:SurgicalMember2024-01-012024-09-290000096943tfx:InterventionalUrologyMember2025-06-302025-09-280000096943tfx:InterventionalUrologyMember2024-07-012024-09-290000096943tfx:InterventionalUrologyMember2025-01-012025-09-280000096943tfx:InterventionalUrologyMember2024-01-012024-09-290000096943tfx:OemMember2025-06-302025-09-280000096943tfx:OemMember2024-07-012024-09-290000096943tfx:OemMember2025-01-012025-09-280000096943tfx:OemMember2024-01-012024-09-290000096943tfx:OtherMember2025-06-302025-09-280000096943tfx:OtherMember2024-07-012024-09-290000096943tfx:OtherMember2025-01-012025-09-280000096943tfx:OtherMember2024-01-012024-09-290000096943tfx:VascularInterventionBusinessMember2025-06-302025-06-300000096943tfx:TermLoanMembertfx:VascularInterventionBusinessMemberus-gaap:LineOfCreditMember2025-06-290000096943us-gaap:RevolvingCreditFacilityMembertfx:VascularInterventionBusinessMemberus-gaap:LineOfCreditMember2025-06-290000096943tfx:VascularInterventionBusinessMember2025-06-3000000969432025-06-300000096943tfx:VascularInterventionBusinessMemberus-gaap:IntellectualPropertyMember2025-06-300000096943tfx:VascularInterventionBusinessMemberus-gaap:IntellectualPropertyMember2025-06-302025-06-300000096943tfx:VascularInterventionBusinessMemberus-gaap:CustomerRelationshipsMember2025-06-300000096943tfx:VascularInterventionBusinessMemberus-gaap:CustomerRelationshipsMember2025-06-302025-06-300000096943tfx:VascularInterventionBusinessMember2025-06-290000096943tfx:VascularInterventionBusinessMember2025-01-012025-09-280000096943tfx:VascularInterventionBusinessMember2025-06-302025-09-280000096943tfx:VascularInterventionBusinessMember2024-07-012024-09-290000096943tfx:VascularInterventionBusinessMember2024-01-012024-09-290000096943tfx:SpecialTerminationBenefitAndOtherRestructuringMembersrt:MinimumMembertfx:A2023FootprintRealignmentPlanMember2025-09-280000096943tfx:SpecialTerminationBenefitAndOtherRestructuringMembersrt:MaximumMembertfx:A2023FootprintRealignmentPlanMember2025-09-280000096943tfx:AcceleratedDepreciationAndOtherCostsMembersrt:MinimumMembertfx:A2023FootprintRealignmentPlanMember2025-09-280000096943tfx:AcceleratedDepreciationAndOtherCostsMembersrt:MaximumMembertfx:A2023FootprintRealignmentPlanMember2025-09-280000096943srt:MinimumMembertfx:A2023FootprintRealignmentPlanMember2025-09-280000096943srt:MaximumMembertfx:A2023FootprintRealignmentPlanMember2025-09-280000096943tfx:A2023FootprintRealignmentPlanMember2025-06-302025-09-280000096943tfx:A2023FootprintRealignmentPlanMember2025-01-012025-09-280000096943tfx:A2023FootprintRealignmentPlanMember2023-09-012025-09-280000096943tfx:A2023FootprintRealignmentPlanMember2025-09-280000096943us-gaap:SpecialTerminationBenefitsMembertfx:A2024RestructuringPlanMember2025-06-302025-09-280000096943us-gaap:OtherRestructuringMembertfx:A2024RestructuringPlanMember2025-06-302025-09-280000096943tfx:A2024RestructuringPlanMember2025-06-302025-09-280000096943us-gaap:SpecialTerminationBenefitsMembertfx:A2024FootprintRealignmentPlanMember2025-06-302025-09-280000096943us-gaap:OtherRestructuringMembertfx:A2024FootprintRealignmentPlanMember2025-06-302025-09-280000096943tfx:A2024FootprintRealignmentPlanMember2025-06-302025-09-280000096943us-gaap:SpecialTerminationBenefitsMembertfx:A2023FootprintRealignmentPlanMember2025-06-302025-09-280000096943us-gaap:OtherRestructuringMembertfx:A2023FootprintRealignmentPlanMember2025-06-302025-09-280000096943us-gaap:SpecialTerminationBenefitsMembertfx:OtherrestructuringprogramsMember2025-06-302025-09-280000096943us-gaap:OtherRestructuringMembertfx:OtherrestructuringprogramsMember2025-06-302025-09-280000096943tfx:OtherrestructuringprogramsMember2025-06-302025-09-280000096943us-gaap:SpecialTerminationBenefitsMember2025-06-302025-09-280000096943us-gaap:OtherRestructuringMember2025-06-302025-09-280000096943us-gaap:SpecialTerminationBenefitsMembertfx:A2024FootprintRealignmentPlanMember2024-07-012024-09-290000096943us-gaap:OtherRestructuringMembertfx:A2024FootprintRealignmentPlanMember2024-07-012024-09-290000096943tfx:A2024FootprintRealignmentPlanMember2024-07-012024-09-290000096943us-gaap:SpecialTerminationBenefitsMembertfx:A2023RestructuringPlanMember2024-07-012024-09-290000096943us-gaap:OtherRestructuringMembertfx:A2023RestructuringPlanMember2024-07-012024-09-290000096943tfx:A2023RestructuringPlanMember2024-07-012024-09-290000096943us-gaap:SpecialTerminationBenefitsMembertfx:A2023FootprintRealignmentPlanMember2024-07-012024-09-290000096943us-gaap:OtherRestructuringMembertfx:A2023FootprintRealignmentPlanMember2024-07-012024-09-290000096943tfx:A2023FootprintRealignmentPlanMember2024-07-012024-09-290000096943us-gaap:SpecialTerminationBenefitsMembertfx:OtherrestructuringprogramsMember2024-07-012024-09-290000096943us-gaap:OtherRestructuringMembertfx:OtherrestructuringprogramsMember2024-07-012024-09-290000096943tfx:OtherrestructuringprogramsMember2024-07-012024-09-290000096943us-gaap:SpecialTerminationBenefitsMember2024-07-012024-09-290000096943us-gaap:OtherRestructuringMember2024-07-012024-09-290000096943us-gaap:SpecialTerminationBenefitsMembertfx:A2024RestructuringPlanMember2025-01-012025-09-280000096943us-gaap:OtherRestructuringMembertfx:A2024RestructuringPlanMember2025-01-012025-09-280000096943tfx:A2024RestructuringPlanMember2025-01-012025-09-280000096943us-gaap:SpecialTerminationBenefitsMembertfx:A2024FootprintRealignmentPlanMember2025-01-012025-09-280000096943us-gaap:OtherRestructuringMembertfx:A2024FootprintRealignmentPlanMember2025-01-012025-09-280000096943tfx:A2024FootprintRealignmentPlanMember2025-01-012025-09-280000096943us-gaap:SpecialTerminationBenefitsMembertfx:A2023FootprintRealignmentPlanMember2025-01-012025-09-280000096943us-gaap:OtherRestructuringMembertfx:A2023FootprintRealignmentPlanMember2025-01-012025-09-280000096943us-gaap:SpecialTerminationBenefitsMembertfx:OtherrestructuringprogramsMember2025-01-012025-09-280000096943us-gaap:OtherRestructuringMembertfx:OtherrestructuringprogramsMember2025-01-012025-09-280000096943tfx:OtherrestructuringprogramsMember2025-01-012025-09-280000096943us-gaap:SpecialTerminationBenefitsMember2025-01-012025-09-280000096943us-gaap:OtherRestructuringMember2025-01-012025-09-280000096943us-gaap:SpecialTerminationBenefitsMembertfx:A2024FootprintRealignmentPlanMember2024-01-012024-09-290000096943us-gaap:OtherRestructuringMembertfx:A2024FootprintRealignmentPlanMember2024-01-012024-09-290000096943tfx:A2024FootprintRealignmentPlanMember2024-01-012024-09-290000096943us-gaap:SpecialTerminationBenefitsMembertfx:A2023RestructuringPlanMember2024-01-012024-09-290000096943us-gaap:OtherRestructuringMembertfx:A2023RestructuringPlanMember2024-01-012024-09-290000096943tfx:A2023RestructuringPlanMember2024-01-012024-09-290000096943us-gaap:SpecialTerminationBenefitsMembertfx:A2023FootprintRealignmentPlanMember2024-01-012024-09-290000096943us-gaap:OtherRestructuringMembertfx:A2023FootprintRealignmentPlanMember2024-01-012024-09-290000096943tfx:A2023FootprintRealignmentPlanMember2024-01-012024-09-290000096943us-gaap:SpecialTerminationBenefitsMembertfx:OtherrestructuringprogramsMember2024-01-012024-09-290000096943us-gaap:OtherRestructuringMembertfx:OtherrestructuringprogramsMember2024-01-012024-09-290000096943tfx:OtherrestructuringprogramsMember2024-01-012024-09-290000096943us-gaap:SpecialTerminationBenefitsMember2024-01-012024-09-290000096943us-gaap:OtherRestructuringMember2024-01-012024-09-290000096943tfx:TitanSGSMember2025-06-302025-09-280000096943tfx:TitanSGSMember2025-01-012025-09-280000096943tfx:CertainLeasedFacilitiesMember2025-01-012025-09-280000096943tfx:CertainLeasedFacilitiesMember2024-01-012024-09-290000096943tfx:AmericasSegmentMember2024-12-310000096943tfx:EMEASegmentMember2024-12-310000096943tfx:AsiaSegmentMember2024-12-310000096943tfx:AmericasSegmentMember2025-01-012025-09-280000096943tfx:EMEASegmentMember2025-01-012025-09-280000096943tfx:AsiaSegmentMember2025-01-012025-09-280000096943tfx:AmericasSegmentMember2025-09-280000096943tfx:EMEASegmentMember2025-09-280000096943tfx:AsiaSegmentMember2025-09-280000096943us-gaap:CustomerRelationshipsMember2025-09-280000096943us-gaap:CustomerRelationshipsMember2024-12-310000096943us-gaap:InProcessResearchAndDevelopmentMember2025-09-280000096943us-gaap:InProcessResearchAndDevelopmentMember2024-12-310000096943us-gaap:IntellectualPropertyMember2025-09-280000096943us-gaap:IntellectualPropertyMember2024-12-310000096943us-gaap:DistributionRightsMember2025-09-280000096943us-gaap:DistributionRightsMember2024-12-310000096943us-gaap:TradeNamesMember2025-09-280000096943us-gaap:TradeNamesMember2024-12-310000096943us-gaap:NoncompeteAgreementsMember2025-09-280000096943us-gaap:NoncompeteAgreementsMember2024-12-310000096943tfx:TitanSGSMember2025-01-012025-03-290000096943tfx:TitanSGSMember2025-09-280000096943us-gaap:RevolvingCreditFacilityMember2024-01-012024-12-310000096943us-gaap:RevolvingCreditFacilityMember2025-01-012025-09-280000096943us-gaap:RevolvingCreditFacilityMember2025-09-280000096943us-gaap:RevolvingCreditFacilityMember2024-12-310000096943tfx:ThreePointFiveSevenPercentTermLoanFacilityMembertfx:TermLoanMember2025-09-280000096943tfx:ThreePointFiveSevenPercentTermLoanFacilityMembertfx:TermLoanMember2024-12-310000096943tfx:ThirdAmendedAndRestatedCreditAgreementMembertfx:TermLoanMember2025-09-280000096943tfx:ThirdAmendedAndRestatedCreditAgreementMembertfx:TermLoanMember2024-12-310000096943tfx:FourPointSixTwoFivePercentSeniorSubordinatedNotesDueTwoThousandTwentySevenMemberus-gaap:SeniorNotesMember2024-12-310000096943tfx:FourPointSixTwoFivePercentSeniorSubordinatedNotesDueTwoThousandTwentySevenMemberus-gaap:SeniorNotesMember2025-09-280000096943tfx:FourPointTwentyFivePercentSeniorNotesDue2028Memberus-gaap:SeniorNotesMember2024-12-310000096943tfx:FourPointTwentyFivePercentSeniorNotesDue2028Memberus-gaap:SeniorNotesMember2025-09-280000096943tfx:SecuritizationProgramMember2024-12-310000096943tfx:SecuritizationProgramMember2025-09-280000096943tfx:ThirdAmendedAndRestatedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2025-09-280000096943us-gaap:FederalFundsEffectiveSwapRateMembertfx:ThirdAmendedAndRestatedCreditAgreementMembersrt:MinimumMember2025-06-302025-09-280000096943tfx:ThirdAmendedAndRestatedCreditAgreementMembertfx:AdjustedSOFRMember2025-06-302025-09-280000096943tfx:AdjustedSOFRMembertfx:ThirdAmendedAndRestatedCreditAgreementMembersrt:MinimumMember2025-06-302025-09-280000096943tfx:AdjustedSOFRMembertfx:ThirdAmendedAndRestatedCreditAgreementMembersrt:MaximumMember2025-06-302025-09-280000096943tfx:ThirdAmendedAndRestatedCreditAgreementMembertfx:AdjustedSOFROneMonthCreditSpreadMember2025-06-302025-09-280000096943tfx:AdjustedSOFRMembertfx:ThirdAmendedAndRestatedCreditAgreementMembersrt:MinimumMembertfx:TermLoanMember2025-06-302025-09-280000096943tfx:AdjustedSOFRMembertfx:ThirdAmendedAndRestatedCreditAgreementMembersrt:MaximumMembertfx:TermLoanMember2025-06-302025-09-280000096943us-gaap:BaseRateMembertfx:ThirdAmendedAndRestatedCreditAgreementMembersrt:MinimumMember2025-06-302025-09-280000096943us-gaap:BaseRateMembertfx:ThirdAmendedAndRestatedCreditAgreementMembersrt:MaximumMember2025-06-302025-09-280000096943tfx:ThirdAmendedAndRestatedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2025-06-302025-09-280000096943tfx:ThirdAmendedAndRestatedCreditAgreementMembertfx:TermLoanMember2025-06-240000096943tfx:VascularInterventionBusinessMembertfx:TermLoanMember2025-06-300000096943tfx:ThirdAmendedAndRestatedCreditAgreementMemberus-gaap:SeniorNotesMember2025-09-280000096943us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2025-02-280000096943us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2025-06-302025-09-280000096943us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2025-01-012025-09-280000096943us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2024-07-012024-09-290000096943us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2024-01-012024-09-290000096943us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2025-09-280000096943us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2024-12-310000096943us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2025-09-280000096943us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2024-12-310000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2025-08-180000096943tfx:CrossCurrencyInterestRateContractExpiring2030Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMember2025-08-180000096943tfx:CrossCurrencyInterestRateContractExpiring2030Memberus-gaap:DesignatedAsHedgingInstrumentMember2025-08-180000096943tfx:CrossCurrencyInterestRateContractExpiring2030Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LongMember2025-08-180000096943tfx:CrossCurrencyInterestRateContractExpiring2032Memberus-gaap:DesignatedAsHedgingInstrumentMember2025-08-180000096943tfx:CrossCurrencyInterestRateContractExpiring2032Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMember2025-08-180000096943tfx:CrossCurrencyInterestRateContractExpiring2032Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LongMember2025-08-180000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-04-250000096943tfx:CrossCurrencyInterestRateContractExpiring2027Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMember2024-04-250000096943tfx:CrossCurrencyInterestRateContractExpiring2027Memberus-gaap:DesignatedAsHedgingInstrumentMember2024-04-250000096943tfx:CrossCurrencyInterestRateContractExpiring2027Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LongMember2024-04-250000096943tfx:CrossCurrencyInterestRateContractExpiring2029Memberus-gaap:DesignatedAsHedgingInstrumentMember2024-04-250000096943tfx:CrossCurrencyInterestRateContractExpiring2029Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMember2024-04-250000096943tfx:CrossCurrencyInterestRateContractExpiring2029Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LongMember2024-04-250000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMember2023-12-310000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LongMember2023-12-310000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMember2025-06-302025-09-280000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMember2024-07-012024-09-290000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMember2025-01-012025-09-280000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMember2024-01-012024-09-290000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NondesignatedMember2025-06-302025-09-280000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NondesignatedMember2024-07-012024-09-290000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NondesignatedMember2025-01-012025-09-280000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NondesignatedMember2024-01-012024-09-290000096943us-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2025-09-280000096943us-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2024-12-310000096943us-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:CashFlowHedgingMember2025-09-280000096943us-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:CashFlowHedgingMember2024-12-310000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:CashFlowHedgingMember2025-09-280000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:CashFlowHedgingMember2024-12-310000096943us-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CashFlowHedgingMember2025-09-280000096943us-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CashFlowHedgingMember2024-12-310000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherAssetsMemberus-gaap:NondesignatedMemberus-gaap:CashFlowHedgingMember2025-09-280000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherAssetsMemberus-gaap:NondesignatedMemberus-gaap:CashFlowHedgingMember2024-12-310000096943us-gaap:CashFlowHedgingMemberus-gaap:OtherAssetsMember2025-09-280000096943us-gaap:CashFlowHedgingMemberus-gaap:OtherAssetsMember2024-12-310000096943us-gaap:CashFlowHedgingMember2025-09-280000096943us-gaap:CashFlowHedgingMember2024-12-310000096943us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2025-09-280000096943us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2024-12-310000096943us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:CashFlowHedgingMember2025-09-280000096943us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:CashFlowHedgingMember2024-12-310000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:CashFlowHedgingMember2025-09-280000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:CashFlowHedgingMember2024-12-310000096943us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:CashFlowHedgingMember2025-09-280000096943us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:CashFlowHedgingMember2024-12-310000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:CashFlowHedgingMember2025-09-280000096943us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:CashFlowHedgingMember2024-12-310000096943us-gaap:ForeignExchangeContractMemberus-gaap:OtherLiabilitiesMemberus-gaap:CashFlowHedgingMember2025-09-280000096943us-gaap:ForeignExchangeContractMemberus-gaap:OtherLiabilitiesMemberus-gaap:CashFlowHedgingMember2024-12-310000096943us-gaap:CashFlowHedgingMember2024-07-012024-09-290000096943us-gaap:CashFlowHedgingMember2024-01-012024-09-290000096943us-gaap:CashFlowHedgingMember2025-01-012025-09-280000096943us-gaap:CashFlowHedgingMember2025-06-302025-09-280000096943us-gaap:FairValueInputsLevel1Member2025-09-280000096943us-gaap:FairValueInputsLevel2Member2025-09-280000096943us-gaap:FairValueInputsLevel3Member2025-09-280000096943us-gaap:FairValueInputsLevel1Member2024-12-310000096943us-gaap:FairValueInputsLevel2Member2024-12-310000096943us-gaap:FairValueInputsLevel3Member2024-12-310000096943srt:MaximumMembertfx:StandardBariatricsMember2025-09-280000096943tfx:PaletteMember2025-09-280000096943tfx:StandardBariatricsMember2025-09-280000096943tfx:RevenuebasedPaymentMembertfx:MonteCarloSimulationMemberus-gaap:MeasurementInputDiscountRateMember2025-09-280000096943tfx:RevenuebasedPaymentMembertfx:MonteCarloSimulationMembertfx:MeasurementInputProbabilityOfPaymentMember2025-09-280000096943us-gaap:StockCompensationPlanMember2025-01-012025-09-280000096943us-gaap:StockCompensationPlanMember2025-06-302025-09-2800000969432024-07-3000000969432025-02-2800000969432025-02-282025-02-2800000969432025-04-0900000969432025-04-092025-04-090000096943us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-310000096943us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-310000096943us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310000096943us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-01-012025-09-280000096943us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-01-012025-09-280000096943us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-09-280000096943us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-09-280000096943us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-09-280000096943us-gaap:AccumulatedTranslationAdjustmentMember2025-09-280000096943us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000096943us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000096943us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000096943us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-09-290000096943us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-290000096943us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-290000096943us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-09-290000096943us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-09-290000096943us-gaap:AccumulatedTranslationAdjustmentMember2024-09-290000096943us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-06-302025-09-280000096943us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-07-012024-09-290000096943us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-01-012025-09-280000096943us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-09-290000096943us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2025-06-302025-09-280000096943us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2024-07-012024-09-290000096943us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2025-01-012025-09-280000096943us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2024-01-012024-09-290000096943us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2025-06-302025-09-280000096943us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2024-07-012024-09-290000096943us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2025-01-012025-09-280000096943us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2024-01-012024-09-290000096943us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-06-302025-09-280000096943us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-07-012024-09-290000096943us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-01-012025-09-280000096943us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-290000096943us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2025-06-302025-09-280000096943us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-290000096943us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2025-01-012025-09-280000096943us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-290000096943us-gaap:AccruedLiabilitiesMember2025-09-280000096943tfx:OtherLiabilityMember2025-09-280000096943srt:MinimumMember2025-09-280000096943srt:MaximumMember2025-09-280000096943tfx:ItalianParliamentLegislationMember2025-08-012025-08-310000096943tfx:ItalianParliamentLegislationMember2025-01-012025-09-280000096943tfx:ItalianParliamentLegislationMember2025-06-302025-09-280000096943tfx:ItalianParliamentLegislationMember2025-09-280000096943tfx:AmericasSegmentMember2025-06-302025-09-280000096943tfx:EMEASegmentMember2025-06-302025-09-280000096943tfx:AsiaSegmentMember2025-06-302025-09-280000096943us-gaap:OperatingSegmentsMember2025-06-302025-09-280000096943us-gaap:OperatingSegmentsMembertfx:AmericasSegmentMember2025-06-302025-09-280000096943us-gaap:OperatingSegmentsMembertfx:EMEASegmentMember2025-06-302025-09-280000096943us-gaap:OperatingSegmentsMembertfx:AsiaSegmentMember2025-06-302025-09-280000096943tfx:AmericasSegmentMember2024-07-012024-09-290000096943tfx:EMEASegmentMember2024-07-012024-09-290000096943tfx:AsiaSegmentMember2024-07-012024-09-290000096943us-gaap:OperatingSegmentsMember2024-07-012024-09-290000096943us-gaap:OperatingSegmentsMembertfx:AmericasSegmentMember2024-07-012024-09-290000096943us-gaap:OperatingSegmentsMembertfx:EMEASegmentMember2024-07-012024-09-290000096943us-gaap:OperatingSegmentsMembertfx:AsiaSegmentMember2024-07-012024-09-290000096943us-gaap:OperatingSegmentsMember2025-01-012025-09-280000096943us-gaap:OperatingSegmentsMembertfx:AmericasSegmentMember2025-01-012025-09-280000096943us-gaap:OperatingSegmentsMembertfx:EMEASegmentMember2025-01-012025-09-280000096943us-gaap:OperatingSegmentsMembertfx:AsiaSegmentMember2025-01-012025-09-280000096943tfx:AmericasSegmentMember2024-01-012024-09-290000096943tfx:EMEASegmentMember2024-01-012024-09-290000096943tfx:AsiaSegmentMember2024-01-012024-09-290000096943us-gaap:OperatingSegmentsMember2024-01-012024-09-290000096943us-gaap:OperatingSegmentsMembertfx:AmericasSegmentMember2024-01-012024-09-290000096943us-gaap:OperatingSegmentsMembertfx:EMEASegmentMember2024-01-012024-09-290000096943us-gaap:OperatingSegmentsMembertfx:AsiaSegmentMember2024-01-012024-09-290000096943us-gaap:MaterialReconcilingItemsMember2025-06-302025-09-280000096943us-gaap:MaterialReconcilingItemsMember2024-07-012024-09-290000096943us-gaap:MaterialReconcilingItemsMember2025-01-012025-09-280000096943us-gaap:MaterialReconcilingItemsMember2024-01-012024-09-290000096943us-gaap:CorporateMember2025-06-302025-09-280000096943us-gaap:CorporateMember2024-07-012024-09-290000096943us-gaap:CorporateMember2025-01-012025-09-280000096943us-gaap:CorporateMember2024-01-012024-09-290000096943tfx:CrossCurrencyInterestRateContractExpiring2027Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SubsequentEventMember2025-10-030000096943tfx:CrossCurrencyInterestRateContractExpiring2026Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMemberus-gaap:SubsequentEventMember2025-12-310000096943tfx:CrossCurrencyInterestRateContractExpiring2026Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:LongMemberus-gaap:SubsequentEventMember2025-12-310000096943tfx:SpecialTerminationBenefitAndOtherRestructuringMembersrt:MinimumMembertfx:VIBusinessIntegrationPlanMemberus-gaap:SubsequentEventMember2025-09-290000096943tfx:SpecialTerminationBenefitAndOtherRestructuringMembersrt:MaximumMembertfx:VIBusinessIntegrationPlanMemberus-gaap:SubsequentEventMember2025-09-290000096943tfx:AcceleratedDepreciationAndOtherCostsMembersrt:MinimumMembertfx:VIBusinessIntegrationPlanMemberus-gaap:SubsequentEventMember2025-09-290000096943tfx:AcceleratedDepreciationAndOtherCostsMembersrt:MaximumMembertfx:VIBusinessIntegrationPlanMemberus-gaap:SubsequentEventMember2025-09-290000096943srt:MinimumMembertfx:VIBusinessIntegrationPlanMemberus-gaap:SubsequentEventMember2025-09-290000096943srt:MaximumMembertfx:VIBusinessIntegrationPlanMemberus-gaap:SubsequentEventMember2025-09-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)
☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 28, 2025

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                    .

Commission file number 1-5353

TELEFLEX INCORPORATED

(Exact name of registrant as specified in its charter)

Delaware						23-1147939
(State or other jurisdiction of incorporation or organization)						(I.R.S. employer identification no.)

550 E. Swedesford Rd., Suite 400 Wayne, PA 19087

(Address of principal executive offices and zip code)

(610) 225-6800

(Registrant’s telephone number, including area code)

(None)

(Former Name, Former Address and Former Fiscal Year,

If Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $1.00 per share

TFX

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes   ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes  ☐    No  ☒

The registrant had 44,194,408 shares of common stock, par value $1.00 per share, outstanding as of November 4, 2025.

TELEFLEX INCORPORATED

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED SEPTEMBER 28, 2025

TABLE OF CONTENTS

Page

PART I — FINANCIAL INFORMATION

Item 1:

Financial Statements (Unaudited):

2

Condensed Consolidated Statements of Income

2

Condensed Consolidated Statements of Comprehensive Income

3

Condensed Consolidated Balance Sheets

4

Condensed Consolidated Statements of Cash Flows

5

Condensed Consolidated Statements of Changes in Equity

6

Notes to Condensed Consolidated Financial Statements

7

Item 2:

Management’s Discussion and Analysis of Financial Condition and Results of Operations

26

Item 3:

Quantitative and Qualitative Disclosures About Market Risk

37

Item 4:

Controls and Procedures

37

PART II — OTHER INFORMATION

Item 1:

Legal Proceedings

38

Item 1A:

Risk Factors

38

Item 2:

Unregistered Sales of Equity Securities and Use of Proceeds

38

Item 3:

Defaults Upon Senior Securities

38

Item 4:

Mine Safety Disclosures

38

Item 5:

Other Information

38

Item 6:

Exhibits

40

SIGNATURES

41

1

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

			Three Months Ended												Nine Months Ended
			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
			(Dollars and shares in thousands, except per share)
Net revenues			$	913,021					$	764,375					$	2,394,579					$	2,251,915
Cost of goods sold			461,379						334,203						1,122,413						989,151
Gross profit			451,642						430,172						1,272,166						1,262,764
Selling, general and administrative expenses			281,764						247,257						719,555						740,718
Research and development expenses			57,228						38,726						132,153						117,119
Pension settlement (benefit) charge			—						(5,407)						—						132,732
Goodwill impairment charge			403,925						—						403,925						—
Restructuring charges, separation costs and other impairment charges			117,623						285						144,550						10,799
(Loss) income from continuing operations before interest and taxes			(408,898)						149,311						(128,017)						261,396
Interest expense			31,841						21,058						72,093						64,909
Interest income			(2,163)						(2,298)						(5,723)						(5,751)
(Loss) income from continuing operations before taxes			(438,576)						130,551						(194,387)						202,238
(Benefit) taxes on (loss) income from continuing operations			(29,699)						19,633						(3,198)						(4,586)
(Loss) income from continuing operations			(408,877)						110,918						(191,189)						206,824
Operating (loss) income from discontinued operations			(20)						112						(157)						(639)
(Benefit) taxes on operating (loss) income from discontinued operations			(5)						26						(36)						(146)
(Loss) income from discontinued operations			(15)						86						(121)						(493)
Net (loss) income			$	(408,892)					$	111,004					$	(191,310)					$	206,331
Earnings per share:
Basic:
(Loss) income from continuing operations			$	(9.24)					$	2.37					$	(4.27)					$	4.40
Income (loss) from discontinued operations			—						0.01						—						(0.01)
Net (loss) income			$	(9.24)					$	2.38					$	(4.27)					$	4.39
Diluted:
(Loss) income from continuing operations			$	(9.24)					$	2.36					$	(4.27)					$	4.38
Loss from discontinued operations			—						—						—						(0.01)
Net (loss) income			$	(9.24)					$	2.36					$	(4.27)					$	4.37
Weighted average common shares outstanding
Basic			44,237						46,724						44,755						46,995
Diluted			44,237						47,012						44,755						47,256

The accompanying notes are an integral part of the condensed consolidated financial statements.

2

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

 

			Three Months Ended												Nine Months Ended
			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
			(Dollars in thousands)
Net (loss) income			$	(408,892)					$	111,004					$	(191,310)					$	206,331
Other comprehensive (loss) income, net of tax:
Foreign currency translation, net of tax of $1,861, $7,370, $19,924, and $3,161 for the three and nine month periods, respectively			(9,968)						27,893						58,250						(23,008)
Pension and other postretirement benefit plans adjustment, net of tax of $31, $279, $494 and $(60,452) for the three and nine month periods, respectively			(143)						(877)						(1,600)						88,099
Derivatives qualifying as hedges, net of tax of $(117), $54, $199 and $(91) for the three and nine month periods, respectively			5,087						(6,051)						(3,659)						(8,926)
Other comprehensive (loss) income, net of tax:			(5,024)						20,965						52,991						56,165
Comprehensive (loss) income			$	(413,916)					$	131,969					$	(138,319)					$	262,496

The accompanying notes are an integral part of the condensed consolidated financial statements.

3

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

			September 28, 2025						December 31, 2024
			(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents			$	353,997					$	290,188
Accounts receivable, net			592,652						459,495
Inventories			802,465						600,133
Prepaid expenses and other current assets			154,609						117,851
Prepaid taxes			82,261						3,457
Total current assets			1,985,984						1,471,124
Property, plant and equipment, net			700,586						502,852
Operating lease assets			107,052						108,912
Goodwill			2,537,777						2,632,314
Intangible assets, net			2,410,406						2,268,714
Deferred tax assets			13,509						11,374
Other assets			116,626						102,624
Total assets			$	7,871,940					$	7,097,914
LIABILITIES AND EQUITY
Current liabilities
Current borrowings			$	100,000					$	100,000
Accounts payable			165,908						141,031
Accrued expenses			147,051						143,167
Payroll and benefit-related liabilities			167,735						151,263
Accrued interest			16,766						5,338
Income taxes payable			12,973						41,318
Other current liabilities			162,600						67,243
Total current liabilities			773,033						649,360
Long-term borrowings			2,571,504						1,555,871
Deferred tax liabilities			423,652						391,066
Pension and postretirement benefit liabilities			32,808						20,185
Noncurrent liability for uncertain tax positions			4,592						1,831
Noncurrent operating lease liabilities			97,650						99,154
Other liabilities			146,838						102,307
Total liabilities			4,050,077						2,819,774
Commitments and contingencies
Total shareholders' equity			3,821,863						4,278,140
Total liabilities and shareholders' equity			$	7,871,940					$	7,097,914

The accompanying notes are an integral part of the condensed consolidated financial statements.

4

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

			Nine Months Ended
			September 28, 2025						September 29, 2024
			(Dollars in thousands)
Cash flows from operating activities of continuing operations:
Net (loss) income			$	(191,310)					$	206,331
Adjustments to reconcile net income to net cash provided by operating activities:
Loss from discontinued operations			121						493
Depreciation expense			58,744						54,826
Intangible asset amortization expense			152,224						147,983
Deferred financing costs and debt discount amortization expense			3,181						2,562
Pension settlement charge			—						132,732
Goodwill impairment charge			403,925						—
Changes in contingent consideration			16,075						7,446
Stock-based compensation			22,798						23,727
Asset impairment charge			108,117						2,110
Gain on non-designated foreign currency forward contracts			(82,636)						—
Deferred income taxes, net			(39,049)						(60,648)
Interest benefit on swaps designated as net investment hedges			(13,254)						(12,031)
Other			(4,820)						1,970
Changes in assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable			(93,532)						(25,294)
Inventories			5,695						(9,913)
Prepaid expenses and other assets			(24,930)						40,446
Accounts payable, accrued expenses and other liabilities			(23,893)						(1,623)
Income taxes receivable and payable, net			(108,485)						(75,493)
Net cash provided by operating activities from continuing operations			188,971						435,624
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment			(94,585)						(94,412)
Proceeds from sale of business and assets			6,712						—
Payments for businesses and intangibles acquired, net of cash acquired			(833,171)						(120)
Proceeds on non-designated balance sheet hedges			82,203						—
Insurance settlement proceeds			9,447						—
Net proceeds on swaps designated as net investment hedges			7,612						18,262
Proceeds from sales of investments			—						7,300
Purchase of investments			(5,000)						(7,300)
Net cash used in investing activities from continuing operations			(826,782)						(76,270)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings			1,140,000						130,000
Reduction in borrowings			(121,750)						(188,375)
Repurchase of common stock			(300,000)						(200,000)
Net proceeds from share based compensation plans and related tax impacts			7,161						3,555
Share repurchase excise tax			(1,894)						—
Payments for contingent consideration			(166)						(182)
Dividends paid			(45,242)						(47,808)
Debt extinguishment, issuance and amendment fees			(4,961)						—
Net cash provided by (used in) financing activities from continuing operations			673,148						(302,810)
Cash flows from discontinued operations:
Net cash used in operating activities			(501)						(2,355)
Net cash used in discontinued operations			(501)						(2,355)
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents			18,824						728
Net increase in cash, cash equivalents and restricted cash equivalents			53,660						54,917
Cash, cash equivalents and restricted cash equivalents at the beginning of the period			327,650						222,848
Cash, cash equivalents and restricted cash equivalents at the end of the period			$	381,310					$	277,765

The accompanying notes are an integral part of the condensed consolidated financial statements.

5

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)

			Common Stock												Additional Paid In Capital						Retained Earnings						Accumulated Other Comprehensive Loss						Treasury Stock												Total
			Shares						Dollars																								Shares						Dollars
			(Dollars and shares in thousands, except per share)
Balance at December 31, 2024			48,096						$	48,096					$	781,184					$	4,115,870					$	(316,669)					1,822						$	(350,341)					$	4,278,140
Net income																					95,002																								95,002
Dividends ($0.34 per share)																					(15,244)																								(15,244)
Other comprehensive income																											23,590																		23,590
Shares issued under compensation plans			95						95						7,537																		(31)						7,108						14,740
Repurchase of common stock															(60,000)																		1,725						(242,400)						(302,400)
Deferred compensation															1,336																		—						—						1,336
Balance at March 30, 2025			48,191						48,191						730,057						4,195,628						(293,079)						3,516						(585,633)						4,095,164
Net income																					122,580																								122,580
Dividends ($0.34 per share)																					(15,078)																								(15,078)
Other comprehensive income																											34,425																		34,425
Shares issued under compensation plans			6						6						5,526																		(5)						873						6,405
Repurchase of common stock															64,450																		493						(65,094)						(644)
Deferred compensation			—						—						16																		—						—						16
Balance at June 29, 2025			48,197						48,197						800,049						4,303,130						(258,654)						4,004						(649,854)						4,242,868
Net loss																					(408,892)																								(408,892)
Dividends ($0.34 per share)																					(15,073)																								(15,073)
Other comprehensive loss																											(5,024)																		(5,024)
Shares issued under compensation plans			—						—						7,831																		(1)						153						7,984
Balance at September 28, 2025			48,197						$	48,197					$	807,880					$	3,879,165					$	(263,678)					4,003						$	(649,701)					$	3,821,863

			Common Stock												Additional Paid In Capital						Retained Earnings						Accumulated Other Comprehensive Loss						Treasury Stock												Total
			Shares						Dollars																								Shares						Dollars
			(Dollars and shares in thousands, except per share)
Balance at December 31, 2023			48,046						$	48,046					$	749,712					$	4,109,736					$	(314,405)					1,006						$	(152,101)					$	4,440,988
Net income																					15,289																								15,289
Dividends ($0.34 per share)																					(16,001)																								(16,001)
Other comprehensive income																											53,351																		53,351
Shares issued under compensation plans			35						35						6,166																		(21)						2,244						8,445
Deferred compensation															347																		(5)						791						1,138
Balance at March 31, 2024			48,081						48,081						756,225						4,109,024						(261,054)						980						(149,066)						4,503,210
Net income																					80,038																								80,038
Dividends ($0.34 per share)																					(16,017)																								(16,017)
Other comprehensive loss																											(18,151)																		(18,151)
Shares issued under compensation plans			10						10						8,967																		(5)						655						9,632
Deferred compensation			—						—						2																		—						5						7
Balance at June 30, 2024			48,091						48,091						765,194						4,173,045						(279,205)						975						(148,406)						4,558,719
Net income																					111,004																								111,004
Dividends ($0.34 per share)																					(15,790)																								(15,790)
Other comprehensive loss																											20,965																		20,965
Shares issued under compensation plans			5						5						8,262																		(1)						149						8,416
Repurchase of common stock															(40,000)																		678						(161,600)						(201,600)
Deferred compensation			—						—						—																		—						3						3
Balance at September 29, 2024			48,096						$	48,096					$	733,456					$	4,268,259					$	(258,240)					1,652						$	(309,854)					$	4,481,717

The accompanying notes are an integral part of the condensed consolidated financial statements.

6

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 (all tabular amounts in thousands unless otherwise noted)

Note 1 — Basis of presentation

The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our" and “Teleflex”) are prepared on the same basis as its annual consolidated financial statements.

In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair statement of the financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for the form and content of presentation of financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year.

In accordance with applicable accounting standards and as permitted by Rule 10-01 of Regulation S-X, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in our annual consolidated financial statements. Therefore, our quarterly condensed consolidated financial statements should be read in conjunction with our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. Certain reclassifications have been made to the prior year amounts to conform to the presentation used for the current period.

Supplemental balance sheet information

Cash, cash equivalents, and restricted cash equivalents consisted of the following at September 28, 2025 and December 31, 2024:

			September 28, 2025						December 31, 2024
Cash and cash equivalents			$	353,997					$	290,188
Restricted cash equivalents in prepaid and other current assets (1)			14,700						14,700
Restricted cash equivalents in other assets (1)			12,613						22,762
Total cash, cash equivalents and restricted cash equivalents			$	381,310					$	327,650

(1) Restricted cash equivalents represent surplus plan assets resulting from the termination of the Teleflex Incorporated Retirement Income Plan (the "TRIP") that were transferred to a suspense account within the Teleflex 401(k) Savings Plan in 2024. These assets are restricted for future use in accordance with our election to use the surplus plan assets from the TRIP to fund future employer contributions to participants in the Teleflex 401(k) Savings Plan. Amounts classified as other current assets are expected to be transferred from the suspense account to employees within one year.

Note 2 — Recently issued accounting standards

In December 2023, the FASB issued new guidance designed to improve income tax disclosure requirements, primarily through increased disaggregation disclosures within the effective tax rate reconciliation as well as enhanced disclosures on income taxes paid. The guidance is effective for all fiscal years beginning after December 15, 2024. The new standard can be adopted on a prospective basis with an option for it to be adopted retrospectively. We are currently evaluating this guidance to determine its impact on our consolidated financial statements.

In November 2024, the FASB issued new guidance designed to enhance disclosures regarding the nature of expenses included in the income statement. The guidance requires tabular disclosures that disaggregate information about prescribed expense categories within relevant income statement expense captions. The guidance is effective for all fiscal years beginning after December 15, 2026 and for interim periods beginning after December 15, 2027. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively

7

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

and early adoption is permitted. We are currently evaluating this guidance to determine its impact on our consolidated financial statements.

In September 2025, the FASB issued new guidance designed to clarify and modernize the accounting for costs related to internal-use software. The updated guidance is intended to provide enhanced transparency and consistency in the capitalization and expensing of software development costs, particularly in incremental and iterative development environments. The guidance is effective for all fiscal years beginning after December 15, 2027, and interim periods within those fiscal years. Entities may apply the guidance using a prospective, retrospective or modified transition approach. Early adoption is permitted. We are currently evaluating this guidance to determine its impact on our consolidated financial statements.

From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believe the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position.

Note 3 — Net revenues

We primarily generate revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with our customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when our products are shipped from the manufacturing or distribution facility. For our Original Equipment and Development Services ("OEM") product category, included within our Americas segment, most revenue is recognized over time because OEM generates revenue from the sale of custom products that have no alternative use and we have an enforceable right to payment to the extent that performance has been completed. We market and sell products through our direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers, which constituted 88%, 10% and 2% of consolidated net revenues, respectively, for the nine months ended September 28, 2025. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods. With respect to the custom products sold in OEM, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice.

The following table disaggregates revenue by global product category for the three and nine months ended September 28, 2025 and September 29, 2024.

			Three Months Ended												Nine Months Ended
			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
Vascular access			$	191,021					$	180,896					$	558,919					$	543,355
Interventional			266,412						149,865						573,990						425,687
Anesthesia			101,449						101,154						284,429						299,997
Surgical			122,879						111,746						342,706						328,574
Interventional urology			71,770						83,395						219,125						246,241
OEM			80,412						82,558						222,971						259,080
Other (1)			79,078						54,761						192,439						148,981
Net revenues (2)			$	913,021					$	764,375					$	2,394,579					$	2,251,915

(1)    Includes revenues generated from sales of our respiratory and urology products (other than interventional urology products) as well as adjustments in our reserves related to the Italian payback measure pertaining to prior years. Refer to Note 13 for additional information.

(2)    The product categories listed above are presented on a global basis, as each of our reportable segments are defined based on the geographic location of its operations.

8

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Note 4 — Acquisition

On June 30, 2025, the first day of the third fiscal quarter of 2025, we completed the acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG (the "VI Business"). The acquisition adds a broad suite of coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters, which complements our interventional product portfolio. Under the terms of the acquisition agreement, we acquired the VI Business for a net initial cash payment of €704.3 million, or $825.2 million, subject to certain working capital and other customary adjustments. The initial payment, along with transaction-related costs and other associated requirements, was financed through $700 million of borrowings under a delayed draw term loan facility as well as $140 million of borrowings under our revolving credit facility.

In connection with the acquisition, we also entered into several ancillary agreements with BIOTRONIK SE & Co. KG to help facilitate business continuity and the integration of the business. These agreements primarily relate to transition support and distribution services and have varying durations extending up to 36 months. We account for these services separately from the business combination, as they were negotiated primarily to benefit Teleflex and do not represent part of the consideration transferred for the acquisition.

The following table presents the fair value of the assets acquired and liabilities assumed with the acquisition of the VI Business:

Assets
Accounts receivable			$	27,653
Inventories			165,834
Prepaid expenses and other current assets			5,017
Total current assets			198,504
Property, plant and equipment			144,580
Operating lease assets			11,827
Intangible assets			382,072
Goodwill			252,382
Deferred tax assets			613
Other assets			3,288
Total noncurrent assets			794,762
Total assets			993,266
Liabilities
Accounts payable			18,789
Accrued expenses			5,398
Payroll and benefit-related liabilities			23,173
Other current liabilities			4,522
Total current liabilities			51,882
Deferred tax liabilities			88,704
Pension and postretirement benefit liabilities			12,995
Noncurrent liability for uncertain tax positions			3,086
Noncurrent operating lease liabilities			8,908
Other liabilities			2,534
Total liabilities			168,109
Net assets acquired			$	825,157

9

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The following table sets forth the fair values and useful lives of the components of identifiable intangible assets acquired as of the date of the acquisition of the VI Business:

			Fair value						Useful life (years)
Intellectual property			$	206,272					8
Customer relationships			175,800						10

The goodwill resulting from the acquisition of the VI Business primarily reflects synergies currently expected to be realized from the integration of the acquired business. The tax-deductible portion of the total goodwill resulting from the acquisition amounts to $34.7 million.

We are continuing to evaluate the fair value of the acquired assets and liabilities assumed in connection with the acquisition and further adjustments may be necessary as a result of our assessment of additional information, primarily deferred tax liabilities, certain intangible assets and goodwill. Additionally, the purchase accounting remains incomplete with respect to the consideration transferred as we have not reached agreement on the closing statement adjustments with the seller. Adjustments during the measurement period will be recognized in the reporting period when they are settled.

For the nine months ended September 28, 2025, we incurred acquisition-related costs associated with the acquisition of the VI Business of $15.8 million, which were recognized in selling, general and administrative expenses in the Condensed Consolidated Statement of Income.

The following unaudited pro forma combined financial information for the three and nine months ended September 28, 2025 and September 29, 2024, respectively, gives effect to the acquisition of the VI Business as if it was completed at the beginning of the earliest period presented. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have occurred under our ownership and management.

			Three Months Ended												Nine Months Ended
			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
			(Dollars and shares in thousands, except per share)
Net revenue			$	913,021					$	859,584					$	2,593,531					$	2,553,613
Net income			(374,683)						89,942						(166,912)						100,802

The unaudited pro forma combined financial information presented above includes the accounting effects of the acquisition of the VI Business, including, to the extent applicable, amortization charges from acquired intangible assets; interest expense associated with borrowings to finance the acquisition; amortization related to the revaluation of inventory and depreciation associated with the step up in fair value of fixed assets; and the related tax effects. The unaudited pro forma financial information also includes non-recurring charges specifically related to the VI Business acquisition. For the three and nine months ended September 28, 2025 we recognized post-acquisition revenue and a pre-tax operating loss related to the VI Business of $101.8 million and $41.8 million, respectively. The pre-tax operating loss reflects the impact of the amortization of the step-up in carrying value of inventory and intangible assets recognized in connection with the acquisition as well as acquisition-related costs.

Note 5 — Restructuring charges, separation costs and impairment charges

2023 Footprint realignment plan

In 2023, we initiated the "2023 Footprint realignment plan," a restructuring plan primarily involving the relocation of certain manufacturing operations to existing lower-cost locations, the outsourcing of certain manufacturing processes and related workforce reductions. These actions are expected to be substantially completed by the end of 2027. The following table provides a summary of the cost estimates by major type of expense associated with the 2023 Footprint realignment plan:

10

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

2023 Footprint Realignment plan

Plan expense estimates:

(Dollars in millions)

Restructuring charges (1)

$4 million to $6 million

Restructuring related charges (2)

$7 million to $9 million

Total restructuring and restructuring related charges

$11 million to $15 million

(1)Substantially all of the charges consist of employee termination benefit costs.

(2)Restructuring related charges represent costs that are directly related to the program and principally constitute costs to transfer manufacturing operations to existing lower-cost locations and project management costs. Substantially all of these charges are expected to be recognized within cost of goods sold.

Additionally, we expect to incur $2 million to $3 million in aggregate capital expenditures under the plan.

For the three and nine months ended September 28, 2025, respectively, we incurred $0.6 million and $2.1 million under the 2023 Footprint realignment plan in restructuring related charges, all of which were recognized in cost of goods sold. As of September 28, 2025, we have incurred aggregate restructuring charges in connection with the 2023 Footprint realignment plan of $3.2 million. In addition, as of September 28, 2025, we have incurred aggregate restructuring related charges of $4.8 million with respect to the 2023 Footprint realignment plan, consisting of certain costs that principally resulted from the transfer of manufacturing operations to new locations.

As of September 28, 2025, we had a restructuring reserve of $2.7 million related to this plan, all of which related to termination benefits.

2024 Restructuring plan

During the fourth quarter of 2024, we initiated the "2024 restructuring plan," which included initiatives to optimize operations, reduce costs and enhance efficiencies across our business lines, including the relocation of select office administrative operations. The plan is substantially complete and as a result, we expect future restructuring expenses associated with the plan to be immaterial.

2024 Footprint realignment plan

During the second quarter of 2024, we initiated the "2024 Footprint realignment plan," encompassing several strategic restructuring initiatives. These initiatives primarily include the relocation of select manufacturing operations to existing lower-cost locations, the optimization of specific product portfolios through targeted rationalization efforts, the relocation of certain integral product development and manufacturing support functions, the optimization of certain supply chain activities and related workforce reductions. The plan is substantially complete and as a result, we expect future restructuring expenses associated with the plan to be immaterial.

Restructuring charges, separation costs and impairment charges recognized for the three and nine months ended September 28, 2025 and September 29, 2024 consisted of the following:

Three Months Ended September 28, 2025
			Termination Benefits						Other Costs (1)						Total
2024 Restructuring plan			$	—					$	6					$	6
2024 Footprint realignment plan			1,451						124						1,575
2023 Footprint realignment plan			—						13						13
Other restructuring programs (2)			—						2						2
Restructuring charges			1,451						145						1,596
Asset impairment charges			—						100,000						100,000
Separation costs			—						16,027						16,027
Restructuring charges, separation costs and other impairment charges			$	1,451					$	116,172					$	117,623

11

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Three Months Ended September 29, 2024
			Termination Benefits						Other Costs (1)						Total
2024 Footprint realignment plan			$	1,066					$	27					$	1,093
2023 Restructuring plan			(95)						—						(95)
2023 Footprint realignment plan			301						—						301
Other restructuring programs (3)			(1,018)						4						(1,014)
Restructuring charges			$	254					$	31					$	285

Nine Months Ended September 28, 2025
			Termination Benefits						Other Costs (1)						Total
2024 Restructuring plan			$	161					$	66					$	227
2024 Footprint realignment plan			3,617						216						3,833
2023 Footprint realignment plan			330						15						345
Other restructuring programs (2)			(143)						27						(116)
Restructuring charges			3,965						324						4,289
Asset impairment charges			—						108,117						108,117
Separation costs			—						32,144						32,144
Restructuring charges, separation costs and other impairment charges			$	3,965					$	140,585					$	144,550

Nine Months Ended September 29, 2024
			Termination Benefits						Other Costs (1)						Total
2024 Footprint realignment plan			$	9,638					$	27					$	9,665
2023 Restructuring plan			(914)						82						(832)
2023 Footprint realignment plan			1,044						3						1,047
Other restructuring programs (3)			(1,225)						34						(1,191)
Restructuring charges			8,543						146						8,689
Asset impairment charges			—						2,110						2,110
Restructuring and other impairment charges			$	8,543					$	2,256					$	10,799

(1) Other costs include facility closure, contract termination and other exit costs.

(2) Includes activity primarily related to our 2023 Restructuring plan and our Respiratory divestiture plan.

(3) Includes activity primarily related to our 2022 Restructuring plan, which has concluded.

Other Impairment charges

For the three and nine months ended September 28, 2025, we recognized an asset impairment charge of $100.0 million related to our Titan SGS asset group, as described in more detail in Note 7. For the nine months ended September 28, 2025 and September 29, 2024, we also recognized impairment charges of $8.1 million and $2.1 million, respectively, primarily related to our cessation of occupancy at certain leased facilities during those periods.

Recently Announced Strategic Actions and Separation Costs

On February 27, 2025, we announced our strategic decision to separate into two independent companies. One company will comprise our Vascular Access product category, most of our products within our Interventional Access and Surgical product categories and the VI Business and will remain with Teleflex. The second company will comprise our Acute Care (consisting of our Urology and Respiratory product categories, the majority of our Anesthesia product category and certain products within our Interventional Access and Surgical product categories), our Interventional Urology and OEM businesses (referred to collectively as "NewCo"). Since announcing the intended separation, we have received a number of inbound expressions of interest in acquiring NewCo and, with oversight of the Board, we continue to actively advance the process for a potential sale of NewCo, which has

12

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

become our primary focus. The completion of any separation transaction will be contingent upon various conditions and approvals, including approval of our Board of Directors, receipt of requisite regulatory clearances and, if applicable, compliance with applicable SEC requirements. There can be no guarantees that the proposed separation will be completed on the terms and within the timeframe we announced, or at all. During the three and nine months ended September 28, 2025, we recognized separation costs of $16.0 million and $32.1 million, respectively, primarily consisting of consulting, legal, tax and other professional advisory services associated with the strategic actions.

Note 6 — Inventories

Inventories as of September 28, 2025 and December 31, 2024 consisted of the following:

			September 28, 2025						December 31, 2024
Raw materials			$	197,051					$	155,201
Work-in-process			149,206						115,814
Finished goods			456,208						329,118
Inventories			$	802,465					$	600,133

Note 7 — Goodwill and other intangible assets

The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the nine months ended September 28, 2025:

			Americas																								EMEA						Asia												Total
December 31, 2024			$	1,932,769																							$	465,489					$	234,056											$	2,632,314
Goodwill impairment			(403,925)																								—						—												(403,925)
Goodwill related to acquisitions			11,766																								185,419						55,197												252,382
Currency translation adjustment			2,892																								45,227						8,887												57,006
September 28, 2025			$	1,543,502																							$	696,135					$	298,140											$	2,537,777

As previously disclosed, our Interventional Urology North America (“IU reporting unit”) has been at risk of impairment since we recognized a goodwill impairment charge for the year ended December 31, 2024 and, as a result, we have been monitoring our IU reporting unit for a potential additional goodwill impairment. During the third quarter of 2025, utilizing various inputs such as the latest business outlook and recent fair value indicators, we determined that there was a deterioration in market and business conditions which resulted in the identification of a triggering event. As a result, in connection with the preparation of the financial statements for the three months ended September 28, 2025, we performed an impairment assessment and determined that the carrying value of the IU reporting unit exceeded its fair value. Consequently, we recognized a goodwill impairment charge of $403.9 million in the Condensed Consolidated Statements of Income for the three months ended September 28, 2025. As of September 28, 2025, there is no remaining goodwill related to the IU reporting unit.

We estimated the fair value of the reporting unit using a market approach, supplemented by an income approach, to validate and support the analysis. The impairment charge was largely driven by unfavorable changes in key assumptions utilized to estimate fair value, relative to our 2024 valuation, specifically, lower market multiples, higher stand-alone operating costs and lower revenue growth.

13

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The gross carrying amount of, and accumulated amortization relating to, intangible assets as of September 28, 2025 and December 31, 2024 were as follows:

			Gross Carrying Amount												Accumulated Amortization
			September 28, 2025						December 31, 2024						September 28, 2025						December 31, 2024
Customer relationships			$	1,540,494					$	1,354,087					$	(679,925)					$	(620,619)
In-process research and development			6,417						23,666						—						—
Intellectual property			2,098,525						1,870,407						(1,038,075)						(863,066)
Distribution rights			19,406						23,004						(18,663)						(22,524)
Trade names			608,459						603,202						(126,232)						(99,443)
Non-compete agreements			21,930						21,894						(21,930)						(21,894)
			$	4,295,231					$	3,896,260					$	(1,884,825)					$	(1,627,546)

We test the recoverability of long-lived assets whenever events or circumstances indicate the carrying value of an asset may not be recoverable. During the first quarter of 2025, we identified indicators of a potential impairment related to the long-lived assets associated with our Titan SGS asset group, acquired as part of our 2022 acquisition of Standard Bariatrics Inc, which primarily consists of intangible assets. The indicators of a potential impairment primarily arose from lower than expected sales of our Titan SGS product line and anticipated continuing reduced demand for bariatric surgery procedures in future periods, driven by the growing adoption of GLP-1 products. We performed a recoverability test, utilizing an updated long-term forecast reflecting higher uncertainty of revenue growth in future periods compared to previous estimates, and concluded that the undiscounted cash flows of the Titan SGS product line exceeded the carrying value of the related assets by approximately 10%. Accordingly, no impairment was recognized during the three months ended March 29, 2025 related to the Titan SGS asset group. During the second quarter of 2025, the Titan SGS product line performed largely in line with the forecast used in the first quarter 2025 recoverability test and no other indicators of a potential impairment were identified.

During the third quarter of 2025, we identified additional indicators of a potential impairment related to the Titan SGS asset group due to lower than expected sales growth during the period and a further downward revision to sales forecasts compared to the forecast utilized in our first quarter 2025 impairment analysis. As a result, in connection with the preparation of the financial statements for the three months ended September 28, 2025, we performed a recoverability test and as a result, we determined that the carrying value of the asset group was not fully recoverable. We subsequently recognized an impairment charge of $100.0 million, representing the amount by which the carrying value of the asset group exceeded its estimated fair value, as determined utilizing the income approach. After the recognition of the impairment charge, the carrying value of the intangible assets of the Titan SGS asset group was $25.1 million.

14

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Note 8 — Borrowings

Our borrowings at September 28, 2025 and December 31, 2024 were as follows:

			September 28, 2025						December 31, 2024
Senior Credit Facility (at a rate of 5.63% at September 28, 2025, due 2027):
Revolving credit facility			$	450,000					$	113,000
Term loan facility			456,250						475,000
Delayed draw term loan			700,000						—
4.625% Senior Notes due 2027			500,000						500,000
4.250% Senior Notes due 2028			500,000						500,000
Securitization program, at a rate of 5.01% at September 28, 2025			75,000						75,000
			2,681,250						1,663,000
Less: Unamortized debt issuance costs			(9,746)						(7,129)
			2,671,504						1,655,871
Current portion of borrowings			(100,000)						(100,000)
Long-term borrowings			$	2,571,504					$	1,555,871

Concurrent with the execution of the agreement to acquire the VI Business described in Note 4, we entered into an amendment to our Third Amended and Restated Credit Agreement (the “Credit Agreement”), which, among other things, (a) provides for a delayed draw term loan facility in an aggregate principal amount of $500 million, to be available to be drawn on the date on which the VI Business acquisition is consummated and (b) permits us to borrow up to $550 million under the revolving facility provided for under the Credit Agreement on a limited condition basis on the date on which the VI Business acquisition is consummated. Borrowings under the delayed draw term loan are to bear interest at a rate per annum equal to the applicable margin plus, at our option, either (1) the highest of (i) the “Prime Rate” in the U.S. last quoted by The Wall Street Journal, (ii) 0.50% above the greater of the federal funds rate and the rate comprised of both overnight federal funds and overnight euro transactions denominated in U.S. dollars and (iii) 1.00% above the Term SOFR Rate for a one-month interest period, plus an applicable margin ranging from 0.125% to 1.00%, in each case subject to adjustments based on our total net leverage ratio, or (2) a Term Secured Overnight Financing Rate (“SOFR”) rate (which includes a credit spread adjustment of 10 basis points). The applicable margin for borrowings under the delayed draw term loan range from 1.125% to 2.00% for SOFR borrowings and from 0.125% to 1.00% for base-rate borrowings, in each case, depending on, at our election, either (x) our public corporate family rating or (y) our consolidated total net leverage ratio, in each case, based on the most recently ended fiscal quarter. The obligations under the delayed draw term loan will be guaranteed and secured on the same basis as the facilities provided for under the Credit Agreement. The delayed draw term loan will not amortize and will mature on the earlier of (x) the date that is two years after the date on which such loans are funded and (y) the maturity date for the revolving facility provided for under the Credit Agreement.

Subsequently, on June 24, 2025, we executed a further amendment to the Credit Agreement, increasing the aggregate principal amount of the delayed term loan facility by $200 million. After giving effect to the amendment, the delayed draw term loan facility provides for an aggregate amount of delayed draw term loan commitments of $700 million. On June 30, 2025, the first day of the third fiscal quarter of 2025, we drew $700 million under the delayed draw term loan facility to fund the VI Business acquisition, inclusive of transaction-related costs and other associated requirements.

As of September 28, 2025, we have capitalized $5.0 million in transaction fees, including underwriters' discounts and commissions incurred in connection with the delayed draw term loan facility.

Note 9 — Financial instruments

Foreign currency forward contracts

We use derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flow hedges are used to manage foreign currency transaction exposure. Foreign currency forward contracts

15

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

not designated as hedges for accounting purposes are used to manage exposure related to near term foreign currency denominated monetary assets and liabilities. We typically enter into the non-designated foreign currency forward contracts for periods consistent with our currency translation exposures, which generally approximate one month. Concurrent with the execution of the agreement to acquire the VI Business as described in Note 4, in February 2025, we also entered into non-designated foreign currency forward contracts with an aggregate notional value of €700 million to hedge economically against the foreign currency exposure associated with the cash consideration required to complete the acquisition. Concurrent with the completion of the VI Business acquisition, on June 30, 2025, we settled these foreign currency forward contracts, which resulted in proceeds of $82.2 million. For the three and nine months ended September 28, 2025, we recognized gains of $0.7 million and $87.1 million, respectively, from non-designated foreign currency forward contracts within selling, general and administrative expenses. For the three and nine months ended September 29, 2024, we recognized a loss of $0.9 million and a gain of $2.6 million, respectively, from non-designated foreign currency forward contracts within selling, general and administrative expenses.

The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of September 28, 2025 and December 31, 2024 was $319.9 million and $270.9 million, respectively. The total notional amount for all open non-designated foreign currency forward contracts as of September 28, 2025 and December 31, 2024 was $282.7 million and $168.6 million, respectively. All open foreign currency forward contracts as of September 28, 2025 have durations of 12 months or less.

Cross-currency interest rate swaps

On August 18, 2025, we executed two separate cross-currency swap agreements set to mature on August 20, 2030 and August 20, 2032, respectively, to hedge against the effect of variability in the U.S. dollar to Swiss Franc (CHF) exchange rate, (the "2025 Cross-currency swap agreements"). Each of the 2025 Cross-currency swap agreements had a notional amount of $300 million and were designated as a net investment hedge. The 2025 Cross-currency swap agreements expiring in 2030 include six different financial institution counterparties and notionally exchanged $300 million for CHF 242.4 million at an annual interest rate of 3.15%. The 2025 Cross-currency swap agreements expiring in 2032 include four different financial institution counterparties and notionally exchanged $300 million for CHF 242.5 million at an annual interest rate of 3.02%.

On April 25, 2024, we executed two separate term cross-currency swap agreements set to mature on February 26, 2027 and February 28, 2029, respectively, to hedge against the effect of variability in the U.S. dollar to euro exchange rate (the "2024 Cross-currency swap agreements"). Each of the 2024 Cross-currency swap agreements had a notional principal amount of $250 million and was designated as a net investment hedge. The 2024 Cross-currency swap agreements expiring in 2027 include five different financial institution counterparties and notionally exchanged $250 million at an annual interest rate of 4.25% for €233.4 million at an annual interest rate of 2.44%. The 2024 Cross-currency swap agreements expiring in 2029 include four different financial institution counterparties and notionally exchanged $250 million at an annual interest rate of 4.25% for €233.4 million at an annual interest rate of 2.45%.

During 2023, we executed cross-currency swap agreements with six different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate, (the "2023 Cross-currency swap agreements"). Under the terms of the 2023 Cross-currency swap agreements, we have notionally exchanged $500 million at an annual interest rate of 4.63% for €474.7 million at an annual interest rate of 3.05%. Shortly after the execution of the 2023 Cross-currency swap agreements, we entered into a zero cost foreign exchange collar contract that aligns with the notional amount and expiration date of the 2023 Cross-currency swap agreements. We sold a put option with a lower strike price and bought a call option with a higher strike price to manage the foreign exchange risk related to the final settlement of the $500 million notional 2023 cross-currency swaps. Upon the execution of the zero cost foreign exchange collar contract, we have de-designated the 2023 Cross-currency swaps and re-designated the combined $500 million notional cross currency swaps and zero cost collar into a new hedging instrument. At redesignation, the existing $500 million notional 2023 cross-currency swaps were off-market due to changes in foreign exchange rates and interest rates. The off-market value due to interest rates will be amortized ratably into earnings through October 2025 and the off-market value due to foreign exchange rates will remain in accumulated other comprehensive income until the underlying net investment is sold. The combined 2023 cross-currency swaps and zero cost collar have been designated as a net investment hedge for accounting purposes. For

16

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

additional information regarding the 2023 Cross-currency swap agreements and the zero cost collar, see Note 15, Subsequent events.

The swap agreements described above require an exchange of the notional amounts upon expiration or earlier termination of the agreements. We and the counterparties have agreed to effect the exchange through a net settlement.

The cross-currency swaps are marked to market at each reporting date and any changes in fair value are recognized as a component of accumulated other comprehensive income (loss) ("AOCI"). The following table summarizes the foreign exchange gains and losses recognized within AOCI and the interest benefit recognized within interest expense related to cross currency swaps for the three and nine months ended September 28, 2025 and September 29, 2024:

			Three Months Ended												Nine Months Ended
			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
Foreign exchange (loss) gain			$	(6,271)					$	(24,846)					$	(89,834)					$	(10,656)
Interest benefit			5,770						4,031						13,254						12,031

Balance sheet presentation

The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of September 28, 2025 and December 31, 2024:

			September 28, 2025						December 31, 2024
			Fair Value
Asset derivatives:
Designated foreign currency forward contracts			$	4,526					$	5,780
Non-designated foreign currency forward contracts			336						254
Cross-currency interest rate swaps			23,198						15,972
Prepaid expenses and other current assets			28,060						22,006
Cross-currency interest rate swaps			946						5,409
Other assets			946						5,409
Total asset derivatives			$	29,006					$	27,415
Liability derivatives:
Designated foreign currency forward contracts			$	4,549					$	3,078
Non-designated foreign currency forward contracts			580						931
Cross-currency interest rate swaps			53,393						9,575
Other current liabilities			58,522						13,584
Cross-currency interest rate swaps			69,791						—
Other liabilities			69,791						—
Total liability derivatives			$	128,313					$	13,584

See Note 11 for information on the location and amount of gains and losses attributable to derivatives that were reclassified from AOCI to expense (income), net of tax. There was no ineffectiveness related to our cash flow hedges during the three and nine months ended September 28, 2025 and September 29, 2024.

Trade receivables

The allowance for credit losses as of September 28, 2025 and December 31, 2024 was $8.5 million and $10.0 million, respectively. The current portion of the allowance for credit losses, which was $4.1 million and $6.1 million as of September 28, 2025 and December 31, 2024, respectively, was recognized as a reduction of accounts receivable, net.

17

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Note 10 — Fair value measurement

The following tables provide information regarding our financial assets and liabilities measured at fair value on a recurring basis as of September 28, 2025 and December 31, 2024:

			Total carrying  value at  September 28, 2025						Quoted prices in active markets (Level 1)						Significant other observable Inputs (Level 2)						Significant unobservable Inputs (Level 3)
Investments in marketable securities			$	35,910					$	35,910					$	—					$	—
Derivative assets			29,006						—						29,006						—
Derivative liabilities			128,313						—						128,313						—
Contingent consideration liabilities			65,186						—						—						65,186

			Total carrying value at December 31, 2024						Quoted prices in active markets (Level 1)						Significant other observable Inputs (Level 2)						Significant unobservable Inputs (Level 3)
Investments in marketable securities			$	39,559					$	39,559					$	—					$	—
Derivative assets			27,415						—						27,415						—
Derivative liabilities			13,584						—						13,584						—
Contingent consideration liabilities			49,277						—						—						49,277

Valuation Techniques

Our financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities, including money market funds. The investment assets are valued using quoted market prices.

Our financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts and cross-currency interest rate swap agreements. We use foreign currency forward contracts and cross-currency interest rate swap agreements to manage foreign currency transaction exposure as well as exposure to foreign currency denominated monetary assets and liabilities. We measure the fair value of the foreign currency forwards and cross-currency swap agreements by calculating the amount required to enter into offsetting contracts with similar remaining maturities, based on quoted market prices, and taking into account the creditworthiness of the counterparties.

Our financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to our acquisitions. Our primary non-recurring fair value estimates, which utilize Level 3 inputs, typically include the following: business acquisitions (Note 4); goodwill impairment testing (Note 7); and asset impairments (Note 5).

Contingent consideration

Contingent consideration liabilities, which primarily consist of payment obligations that are contingent upon the achievement of revenue-based goals, but also can be based on other milestones such as regulatory approvals, are remeasured to fair value each reporting period using assumptions including revenue growth rates (based on internal operational budgets and long-range strategic plans), revenue volatility, discount rates, probability of payment and projected payment dates.

We determine the fair value of certain contingent consideration liabilities using a Monte Carlo simulation (which involves a simulation of future revenues during the earn-out period using management's best estimates) or discounted cash flow analysis. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect. As of September 28, 2025, the maximum amount we may be required to pay under the contingent consideration arrangements was $65 million, of which $50 million and $15 million relate to the Palette Life Sciences AB ("Palette") and the Standard Bariatrics Inc. acquisitions, respectively.

18

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of our significant contingent consideration liabilities.

Contingent Consideration Liability

Valuation Technique

Unobservable Input

Revenue-based

Monte Carlo simulation / Discounted cash flow

Discount rate

6.4%

Probability of payment

100%

Projected year of payment

Prior to the end of 2026

The following table provides information regarding changes in our contingent consideration liabilities for the nine months ended September 28, 2025:

			Contingent consideration
Balance – December 31, 2024			$	49,277
Payments			(166)
Revaluations and other adjustments			16,075
Balance – September 28, 2025			$	65,186

Note 11 — Shareholders' equity

Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding:

			Three Months Ended												Nine Months Ended
			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
Basic			44,237						46,724						44,755						46,995
Dilutive effect of share-based awards			—						288						—						261
Diluted			44,237						47,012						44,755						47,256

The number of basic and diluted shares is the same for the three and nine months ended September 28, 2025 due to our loss from continuing operations. Additionally, because of the loss from continuing operations, for the three and nine months ended September 28, 2025, 0.1 million of potentially dilutive share-based awards were excluded from the computation of loss per share as their effect would have been antidilutive. The weighted average number of antidilutive shares excluded from the calculation of earnings per share were 1.3 million for the three and nine months ended September 28, 2025 and 0.9 million for the three and nine months ended September 29, 2024.

On July 30, 2024, the Board of Directors authorized a share repurchase program for up to $500 million of our common stock. On February 28, 2025, we entered into an accelerated share repurchase agreement for $300 million of our common stock, representing the remainder of the share repurchase program approved by the Board of Directors in 2024. Under this agreement, 1,725,253 shares of common stock, representing 80% of the $300 million aggregate, were delivered and included in treasury stock during the three months ended March 30, 2025. The initial shares received were calculated based on a price per share of $139.11, which was the closing share price of our common stock on February 27, 2025. Final settlement under the agreement occurred on April 9, 2025, at which time we received 493,150 additional shares of common stock. The total shares received were calculated based on a price per share of $135.23, which was based on volume-weighted average prices of our common stock during the accelerated share repurchase period less a discount.

19

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the nine months ended September 28, 2025 and September 29, 2024:

			Cash Flow Hedges						Pension and Other Postretirement Benefit Plans						Foreign Currency Translation Adjustment						Accumulated Other Comprehensive (Loss) Income
Balance as of December 31, 2024			$	1,839					$	1,838					$	(320,346)					$	(316,669)
Other comprehensive (loss) income before reclassifications			(4,864)						(2,548)						58,250						50,838
Amounts reclassified from accumulated other comprehensive income			1,205						948						—						2,153
Net current-period other comprehensive (loss) income			(3,659)						(1,600)						58,250						52,991
Balance as of September 28, 2025			$	(1,820)					$	238					$	(262,096)					$	(263,678)

			Cash Flow Hedges						Pension and Other Postretirement Benefit Plans						Foreign Currency Translation Adjustment						Accumulated Other Comprehensive (Loss) Income
Balance as of December 31, 2023			$	1,396					$	(88,049)					$	(227,752)					$	(314,405)
Other comprehensive income (loss) before reclassifications			(6,249)						8,280						(23,008)						(20,977)
Amounts reclassified from accumulated other comprehensive (loss) income			(2,677)						79,819						—						77,142
Net current-period other comprehensive income			(8,926)						88,099						(23,008)						56,165
Balance as of September 29, 2024			$	(7,530)					$	50					$	(250,760)					$	(258,240)

The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss)/income into (income)/expense, net of tax, for the three and nine months ended September 28, 2025 and September 29, 2024:

			Three Months Ended												Nine Months Ended
			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
(Gains) Loss on foreign exchange contracts:
Cost of goods sold			$	756					$	(589)					$	1,113					$	(2,698)
Total before tax			756						(589)						1,113						(2,698)
Taxes			(15)						7						92						21
Net of tax			741						(582)						1,205						(2,677)
Pension and other postretirement benefit items (1):
Actuarial (gains) losses			16						(48)						55						1,162
Prior-service costs			386						(492)						1,156						(1,475)
Settlements			—						—						—						138,139
Total before tax			402						(540)						1,211						137,826
Tax benefit			(87)						118						(263)						(58,007)
Net of tax			315						(422)						948						79,819
Total reclassifications, net of tax			$	1,056					$	(1,004)					$	2,153					$	77,142

(1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans.

20

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

Note 12 — Taxes on income from continuing operations

Three Months Ended

Nine Months Ended

September 28, 2025

September 29, 2024

September 28, 2025

September 29, 2024

Effective income tax rate (1)

6.8%

15.0%

1.6%

(2.3)%

(1) The effective income tax rates for the three and nine months ended September 28, 2025 and the nine months ended September 29, 2024 represent an income tax benefit. The effective income tax rate for the three months ended September 29, 2024 represents income tax expense.

The effective income tax rates for the three and nine months ended September 28, 2025 and were 6.8% and 1.6%, respectively. The effective income tax rates for the three and nine months ended September 28, 2025 reflect a non-deductible goodwill impairment charge related to the IU reporting unit. Additionally, the effective income tax rates for the three and nine months ended September 28, 2025 reflect a tax benefit associated with the impairment of the Titan SGS asset group. The effective income tax rate for the nine months ended September 28, 2025 reflects non-taxable favorable adjustments incurred in relation to foreign currency exchange rates, largely stemming from non-designated foreign currency forward contracts designed to hedge against the cash consideration for the VI Business acquisition. All periods include a tax benefit from research and development tax credits. The effective income tax rate for the nine months ended September 29, 2024 reflects a tax benefit associated with a pension settlement charge recognized in connection with the termination of the TRIP defined benefit plan.

Note 13 — Commitments and contingent liabilities

Environmental: We are subject to contingencies as a result of environmental laws and regulations that in the future may require us to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by us or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require us to undertake certain investigative and remedial activities at sites where we conduct or once conducted operations or at sites where Company-generated waste was disposed.

Remediation activities vary substantially in duration and cost from site to site. The nature of these activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At September 28, 2025, we have recorded $0.5 million and $3.0 million in accrued liabilities and other liabilities, respectively, relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of September 28, 2025. The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 10-15 years.

Legal matters: We are a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability and product warranty, intellectual property, commercial disputes, acquisition and divestiture related matters, contracts, employment, environmental and other matters. As of September 28, 2025, we have recorded accrued liabilities of $1.9 million in connection with such contingencies, representing our best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters. Amounts accrued for legal contingencies are often determined based on a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions, including as to the timing of related payments. The ability to make such estimates and judgments can be affected by various factors including whether, among other things, damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has commenced or is complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute, or procedural or jurisdictional issues; there is uncertainty or unpredictability regarding the number of potential claims; there is the potential to achieve comprehensive multi-party settlements; there is complexity regarding related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against us, we do not record an accrual until a loss is determined to be probable and can be reasonably estimated.

21

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

While the results of such litigation or claims cannot be predicted with certainty, based on information currently available, advice of counsel, established reserves and other resources, we do not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred.

Other: In 2015, the Italian parliament enacted legislation that, among other things, imposed a “payback” measure on medical device companies that supply goods and services to the Italian National Healthcare System. Under the measure, companies are required to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. The payment amounts are calculated based on the amount by which the regional ceilings for the given year were exceeded. In response to decrees issued by the Italian Ministry of Health, the various Italian regions issued invoices to medical device companies, including Teleflex, under the payback measure in the fourth quarter of 2022 seeking payment with respect to excess expenditures for the years 2015 through 2018. Following the issuance of the invoices, we and numerous other medical device companies filed appeals with the Italian administrative courts challenging the enforceability of the payback measure, primarily on the basis that the law was unconstitutional. The Italian administrative courts referred the question regarding the constitutionality of the law to the Italian Constitutional Court, which in July 2024, issued a ruling upholding the law as constitutional. In August 2025, the Italian parliament enacted a modification to the previously enacted legislation that reduced the payment amounts due from the affected companies, including Teleflex, to approximately 25% of the amounts originally invoiced for the years 2015 through 2018. Payment of the reduced amount precludes the pursuit of further legal action related to the obligation to pay the amounts relating to such years. During the third quarter of 2025, we remitted payment to the related regions to settle the years 2015 through 2018. As a result of the modification in the legislation, along with an adjustment to our calculation of the reserves related to years 2019 through 2025, we recognized a $23.7 million decrease in our reserve (and corresponding increase to revenue for the three and nine months ended September 28, 2025), of which $20.1 million pertains to prior periods. As of September 28, 2025, our reserve related to this matter was $18.3 million.

As part of our acquisition of Palette in 2023, we identified certain foreign tax liabilities that had not been properly recognized and paid by Palette prior to our acquisition. As part of our acquisition accounting, we have established a liability of $4.4 million, representing our best estimate of the outstanding tax liabilities including interest as of September 28, 2025. In February 2024, we requested the relevant foreign tax authority to reassess Palette’s previously filed tax returns for the related periods. In April 2025, we received a notice from the tax authority indicating our request may be subject to challenge. In October 2025, we received a decision denying our request for reassessment. We strongly disagree with the tax authority’s decision and are currently consulting with external legal and tax advisors to evaluate all available options. We intend to defend the position stated in our reassessment request vigorously. If we are unsuccessful in appealing and/or challenging this decision, we may be required to pay an amount in excess of our current established liability, which could be material.

Tax audits and examinations: We are routinely subject to tax examinations by various tax authorities. As of September 28, 2025, the most significant tax examinations in process were in Germany and the United States. We may establish reserves with respect to our uncertain tax positions, after we adjust the reserves to address developments with respect to our uncertain tax positions, including developments in these tax examinations. Accordingly, developments in tax audits and examinations, including resolution of uncertain tax positions, could result in increases or decreases to our recorded tax liabilities, which could impact our financial results.

Note 14 — Segment information

An operating segment is a component (a) that engages in business activities from which it may earn revenues and incur expenses, (b) whose operating results are regularly reviewed by the chief operating decision maker (in our case, our President and Chief Executive Officer) to make decisions about resources to be allocated to the segment and to assess its performance, and (c) for which discrete financial information is available. The chief operating decision maker utilizes segment operating profit to evaluate operating expenses through a comparison of budget to actual results as well as an analysis of operating expenses as a percentage of revenue. We do not

22

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

evaluate our operating segments using discrete asset information.

We have three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Our reportable segments primarily design, manufacture and distribute medical devices primarily used in critical care and surgical applications and generally serve two end-markets: hospitals and healthcare providers, and home health. The products of these segments are most widely used in the acute care setting for a range of diagnostic and therapeutic procedures and in general and specialty surgical applications. The Americas also includes our OEM product portfolio that designs, manufactures and supplies devices and instruments for other medical device manufacturers.

The following tables present our segment results for the three and nine months ended September 28, 2025 and September 29, 2024:

			Three Months Ended September 28, 2025
			Americas						EMEA						Asia						Segment Total
Net revenues			$	555,900					$	234,247					$	122,874					$	913,021
Cost of goods sold			233,349						119,886						65,477						418,712
Research and development expenses			25,171						25,402						4,937						55,510
Selling, general and administrative expenses			121,374						61,379						31,919						214,672
Segment operating profit (1)			$	176,006					$	27,580					$	20,541					$	224,127

			Three Months Ended September 29, 2024
			Americas						EMEA						Asia						Segment Total
Net revenues			$	515,888					$	150,224					$	98,263					$	764,375
Cost of goods sold			205,548						68,238						34,762						308,548
Research and development expenses			22,286						8,693						4,689						35,668
Selling, general and administrative expenses			114,078						38,623						25,089						177,790
Segment operating profit (1)			$	173,976					$	34,670					$	33,723					$	242,369

			Nine Months Ended September 28, 2025
			Americas						EMEA						Asia						Segment Total
Net revenues			$	1,557,261					$	551,633					$	285,685					$	2,394,579
Cost of goods sold			635,856						263,184						129,952						1,028,992
Research and development expenses			67,609						43,536						14,268						125,413
Selling, general and administrative expenses			352,062						143,227						79,933						575,222
Segment operating profit (1)			$	501,734					$	101,686					$	61,532					$	664,952

			Nine Months Ended September 29, 2024
			Americas						EMEA						Asia						Segment Total
Net revenues			$	1,525,503					$	456,944					$	269,468					$	2,251,915
Cost of goods sold			614,864						216,057						96,185						927,106
Research and development expenses			66,464						30,329						13,818						110,611
Selling, general and administrative expenses			347,595						116,449						73,880						537,924
Segment operating profit (1)			$	496,580					$	94,109					$	85,585					$	676,274

(1)Segment operating profit represents income from continuing operations before interest, loss on extinguishment of debt and taxes adjusted to exclude unallocated corporate expenses, manufacturing variances other than fixed manufacturing cost absorption variances, restructuring and impairment charges. See reconciliation of segment operating profit measures for further details.

23

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

			Three Months Ended												Nine Months Ended
			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
Reconciliation of segment operating profit measure
Segment operating profit			$	224,127					$	242,369					$	664,952					$	676,274
Other unallocated expenses (1)			111,477						98,180						244,494						271,347
Pension settlement (benefit) charge			—						(5,407)						—						132,732
Goodwill impairment charge			403,925						—						403,925						—
Restructuring charges, separation costs and other impairment charges			117,623						285						144,550						10,799
(Loss) income from continuing operations before interest and taxes			$	(408,898)					$	149,311					$	(128,017)					$	261,396

(1) Other unallocated expenses include expenses within costs of goods sold, research and development and selling, general and administrative costs and primarily consist of manufacturing variances other than fixed manufacturing cost absorption variances and unallocated corporate function expenses.

			Three Months Ended												Nine Months Ended
Depreciation and amortization			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
Americas			$	47,399					$	47,700					$	139,795					$	143,393
EMEA			19,980						13,083						44,811						36,578
Asia			5,853						3,181						12,298						8,805
Corporate (1)			4,693						4,672						14,064						14,033
Consolidated depreciation and amortization			$	77,925					$	68,636					$	210,968					$	202,809

(1)Reflects depreciation and amortization included within other allocated expenses per reconciliation of segment operating profit measure.

Note 15 — Subsequent events

2023 Cross-currency swap

In the fourth quarter of 2025, and prior to the original October 4, 2025 maturity date, we terminated the 2023 Cross-currency swap agreements and executed new cross-currency swap agreements with five financial institution counterparties. Under these new cross-currency swap agreements, which mature in March 2026, we notionally exchanged $500 million at an annual interest rate of 4.63% for €474.7 million at an annual interest rate of 2.77%. Further, the zero cost foreign exchange collar contract associated with the 2023 Cross-currency swap agreements matured in October 2025 resulting in an immaterial impact to our financial results.

VI Business integration plan

During the fourth quarter of 2025, the Board of Directors approved a restructuring plan related to the integration of the VI Business into Teleflex (the “VI Business Integration plan”). The VI Business Integration plan encompasses the realignment of the global sales force and certain administrative functions, including workforce reductions, and the relocation of certain manufacturing operations to existing lower-cost locations. These actions are expected to be substantially completed by the end of 2028. The following table provides a summary of our estimates of restructuring and restructuring related charges by major type of expense associated with the VI Business Integration plan:

VI Business Integration plan

Plan expense estimates:

(Dollars in millions)

Restructuring charges (1)

$26 million to $31 million

Restructuring related charges (2)

$10 million to $13 million

Total restructuring and restructuring related charges

$36 million to $44 million

24

TELEFLEX INCORPORATED

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

(Unaudited)

(1)Substantially all of the charges consist of employee termination benefit costs.

(2)Restructuring related charges represent costs that are directly related to the program and principally constitute costs to transfer manufacturing operations to existing lower-cost locations and project management costs. The majority of these charges are expected to be recognized within cost of goods sold.

We expect all the restructuring and restructuring related charges will result in future cash outlays, of which, an estimated $12 million to $14 million are expected to occur during 2026. Additionally, we expect to incur $5 million to $7 million in aggregate capital expenditures under the VI Business Integration plan, which are expected to be incurred mostly between 2026 and 2027.

Palette acquisition tax matter

For information regarding subsequent event related to our request to the relevant foreign tax authority to reassess Palette’s previously filed tax returns, refer to Note 13.

25

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Teleflex Incorporated (“we,” “us,” “our" and “Teleflex”) is a global provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products worldwide through a combination of our direct sales force and distributors. Because our products are used in numerous markets and for a variety of procedures, we are not dependent upon any one end-market or procedure. We are focused on achieving consistent, sustainable and profitable growth by increasing our market share and improving our operating efficiencies.

We evaluate our portfolio of products and businesses on an ongoing basis to ensure alignment with our overall objectives. Based on our evaluation, we may identify opportunities to divest businesses and product lines that do not meet our objectives. In addition, we may seek to optimize utilization of our facilities through restructuring initiatives designed to further improve our cost structure and enhance our competitive position. We also may continue to explore opportunities to expand the size of our business and improve operating margins through a combination of acquisitions and distributor to direct sales conversions, which generally involve our elimination of a distributor from the sales channel, either by acquiring the distributor or terminating the distributor relationship (in some instances, particularly in Asia, the conversions involve our acquisition or termination of a master distributor and the continued sale of our products through sub-distributors or through new distributors). Distributor to direct sales conversions are designed to facilitate improved product pricing and more direct access to the end users of our products within the sales channel.

Acquisition of BIOTRONIK Vascular Intervention business

On February 24, 2025, we executed a definitive agreement to acquire substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG (the "VI Business"). The acquisition adds a broad suite of coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters, which complements our interventional product portfolio.

On June 30, 2025, the first day of the third fiscal quarter of 2025, we completed the acquisition of the VI Business for a net initial cash payment of €704.3 million, or $825.2 million, subject to certain working capital and other customary adjustments. Borrowings under the delayed draw term loan, discussed in Note 8 and within the Liquidity and Capital Resources section below, and our revolving credit facility were utilized to finance the acquisition, inclusive of transaction-related costs and other associated requirements.

Concurrent with the execution of the agreement to acquire the VI Business, we entered into foreign exchange derivative contracts with an aggregate notional value of €700 million to hedge economically against the foreign currency exposure associated with the cash consideration needed to complete the acquisition. These forward contracts were settled on June 30, 2025, concurrent with the completion of our acquisition. The settlement of the forward currency contracts resulted in proceeds of $82.2 million.

In connection with the acquisition, we also entered into several ancillary agreements with BIOTRONIK SE & Co. KG to help facilitate business continuity and the integration of the business. These agreements primarily relate to transition support and distribution services and have varying durations extending up to 36 months.

For additional information regarding the acquisition of the VI Business, refer to Note 4 within the condensed consolidated financial statements included in this report.

Recently Announced Strategic Actions

On February 27, 2025, we announced our strategic decision to separate into two independent companies. One company will comprise our Vascular Access product category, most of our products within our Interventional Access and Surgical product categories and the VI Business and will remain with Teleflex. The second company will comprise our Acute Care (consisting of our Urology and Respiratory product categories, the majority of our Anesthesia product category and certain products within our Interventional Access and Surgical product categories), our Interventional Urology and OEM businesses (referred to collectively as "NewCo"). Since announcing the intended separation, we have received a number of inbound expressions of interest in acquiring NewCo and, with oversight of the Board, we continue to actively advance the process for a potential sale of NewCo, which has

26

become our primary focus. There can be no guarantees that the proposed separation will be completed on the terms and within the timeframe we announced, or at all.

Impairment considerations

As previously disclosed, our Interventional Urology North America (“IU reporting unit”) has been at risk of impairment since we recognized a goodwill impairment charge for the year ended December 31, 2024 and, as a result, we have been monitoring our IU reporting unit for a potential additional goodwill impairment. During the third quarter of 2025, utilizing various inputs such as the latest business outlook and recent fair value indicators, we determined that there was a deterioration in market and business conditions which resulted in the identification of a triggering event. As a result, in connection with the preparation of the financial statements for the three months ended September 28, 2025, we performed an impairment assessment and determined that the carrying value of the IU reporting unit exceeded its fair value. Consequently, we recognized a goodwill impairment charge of $403.9 million in the Condensed Consolidated Statements of Income for the three months ended September 28, 2025. As of September 28, 2025, there is no remaining goodwill related to the IU reporting unit.

We estimated the fair value of the reporting unit using a market approach, supplemented by an income approach, to validate and support the analysis. The impairment charge was largely driven by unfavorable changes in key assumptions utilized to estimate fair value, relative to our 2024 valuation, specifically, lower market multiples, higher stand-alone operating costs and lower revenue growth.

We test the recoverability of long-lived assets whenever events or circumstances indicate the carrying value of an asset may not be recoverable. During the first quarter of 2025, we identified indicators of a potential impairment related to the long-lived assets associated with our Titan SGS asset group, which primarily consists of intangible assets. The indicators of a potential impairment primarily arose from lower than expected sales of our Titan SGS product line and anticipated continuing reduced demand for bariatric surgery procedures in future periods, driven by the growing adoption of GLP-1 products. We performed a recoverability test, utilizing an updated long-term forecast reflecting higher uncertainty of revenue growth in future periods compared to previous estimates, and concluded that the undiscounted cash flows of the Titan SGS product line exceeded the carrying value of the related assets by approximately 10%. Accordingly, no impairment was recognized during the three months ended March 29, 2025 related to the Titan SGS asset group. During the second quarter of 2025, the Titan SGS product line performed largely in line with the forecast used in the first quarter 2025 recoverability test.

During the third quarter of 2025, we identified additional indicators of a potential impairment related to the Titan SGS asset group due to lower than expected sales growth during the period and a further downward revision to sales forecasts compared to the forecast utilized in our first quarter 2025 impairment analysis. As a result, in connection with the preparation of the financial statements for the three months ended September 28, 2025, we performed a recoverability test and as a result, we determined that the carrying value of the asset group was not fully recoverable. We subsequently recognized an impairment charge of $100.0 million, representing the amount by which the carrying value of the asset group exceeded its estimated fair value, as determined utilizing the income approach. After the recognition of the impairment charge, the carrying value of the intangible assets of the Titan SGS asset group was $25.1 million. Despite the downward revision to sales forecasts, we continue to anticipate revenue growth from the Titan SGS asset group in future periods.

Tariffs

Our global operations are subject to risks associated with international trade policies, and we continue to closely monitor developments in trade relations and policy, including tariffs. The recently enacted U.S. tariffs and accompanying retaliatory measures, had a negative impact on our gross margins and cash flows for the three and nine months ended September 28, 2025. The impact was primarily driven by higher import costs linked to our operations in the European Union, as well as to products manufactured in Mexico that are not currently compliant with the United States-Mexico-Canada Agreement (USMCA). We are currently evaluating options to mitigate our exposure through supply chain optimization strategies, including modifications to chain of custody protocols and increasing the proportion of products compliant with the USMCA in our portfolio, in addition to customer pricing. Additional changes to proposed and enacted tariffs could have a material impact on our business and we may experience a material negative impact on our gross margins and cash flows in future periods. The ultimate impact of changes to tariffs and trade policies on our results from operations and cash flows will depend on several factors, including the timing, scale, scope, and nature of any tariffs or policies that are implemented, and any associated retaliatory measures.

27

Italian payback measure

In 2015, the Italian parliament enacted legislation that, among other things, imposed a “payback” measure on medical device companies that supply goods and services to the Italian National Healthcare System. Under the measure, companies are required to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. The payment amounts are calculated based on the amount by which the regional ceilings for the given year were exceeded. In response to decrees issued by the Italian Ministry of Health, the various Italian regions issued invoices to medical device companies, including Teleflex, under the payback measure in the fourth quarter of 2022 seeking payment with respect to excess expenditures for the years 2015 through 2018. Following the issuance of the invoices, we and numerous other medical device companies filed appeals with the Italian administrative courts challenging the enforceability of the payback measure, primarily on the basis that the law was unconstitutional. The Italian administrative courts referred the question regarding the constitutionality of the law to the Italian Constitutional Court, which in July 2024, issued a ruling upholding the law as constitutional. In August 2025, the Italian parliament enacted a modification to the previously enacted legislation that reduced the payment amounts due from the affected companies, including Teleflex, to approximately 25% of the amounts originally invoiced for the years 2015 through 2018. Payment of the reduced amount precludes the pursuit of further legal action related to the obligation to pay the amounts relating to such years. During the third quarter of 2025, we remitted payment to the related regions to settle the years 2015 through 2018. As a result of the modification in the legislation, along with an adjustment to our calculation of the reserves related to years 2019 through 2025, we recognized a $23.7 million decrease in our reserve (and corresponding increase to revenue for the three and nine months ended September 28, 2025), of which $20.1 million pertains to prior periods. As of September 28, 2025, our reserve related to this matter was $18.3 million.

Results of Operations

As used in this discussion, "new products" are products for which commercial sales have commenced within the past 36 months, and “existing products” are products for which commercial sales commenced more than 36 months ago. Discussion of results of operations items that reference the effect of one or more acquired and/or divested businesses or assets (except as noted below with respect to acquired distributors) generally reflects the impact of the acquisitions and/or divestitures within the first 12 months following the date of the acquisition and/or divestiture. In addition to increases and decreases in the per unit selling prices of our products to our customers, our discussion of the impact of product price increases and decreases also reflects the impact on the pricing of our products resulting from the elimination of the distributor, either through acquisition or termination of the distributor, from the sales channel. All of the dollar amounts in the tables are presented in millions unless otherwise noted.

Certain financial information is presented on a rounded basis, which may cause minor differences.

Net revenues

			Three Months Ended												Nine Months Ended
			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
Net revenues			$	913.0					$	764.4					$	2,394.6					$	2,251.9

Net revenues for the three months ended September 28, 2025 increased $148.6 million, or 19.4%, compared to the prior year period, primarily due to net revenues of $101.8 million generated by the acquired VI Business, the $23.7 million favorable impact from a decrease in our reserves related to the Italian payback measure, $10.0 million of favorable fluctuations in foreign currency exchange rates and a $9.4 million favorable impact from a stocking order in China related to recently implemented initiatives intended to expand the sales channel of intra-aortic balloon pumps and catheters.

Net revenues for the nine months ended September 28, 2025 increased $142.7 million, or 6.3%, compared to the prior year period, primarily due to net revenues of $101.8 million generated by the acquired VI Business, a $39.5 million net favorable impact from adjustments to our reserves related to the Italian payback measure, driven by the $23.7 million favorable adjustment recognized in the current period compared to an unfavorable adjustment of $15.8 million in the prior period. The increases in net revenues were also impacted by a $26.4 million increase in sales of new products, $9.5 million of favorable fluctuations in foreign currency exchange rates, and a $9.4 million favorable impact from a stocking order in China related to recently implemented initiatives intended to expand the sales channel of intra-aortic balloon pumps and catheters. The increases in net revenues were partially offset by a $47.6 million decrease in sales volumes of existing products, primarily driven by declines in sales related to our OEM product category and UroLift product line.

28

Gross profit

			Three Months Ended												Nine Months Ended
			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
Gross profit			$	451.6					$	430.2					$	1,272.2					$	1,262.8
Percentage of sales			49.5		%				56.3		%				53.1		%				56.1		%

Gross margin for the three months ended September 28, 2025 decreased 680 basis points, or 12.1%, compared to the prior year period, primarily due to the adverse impact from the amortization of the step-up in carrying value of inventory and intangible assets recognized in connection with the VI Business acquisition, the adverse impact from recently enacted tariffs, unfavorable fluctuations in foreign currency exchange rates and an increase in logistics and distribution costs. The decreases in gross margin were partially offset by the favorable impact from a decrease in our reserves related to the Italian payback measure.

Gross margin for the nine months ended September 28, 2025 decreased 300 basis points, or 5.3%, compared to the prior year period, primarily due to the adverse impact from the amortization of the step-up in carrying value of inventory and intangible assets recognized in connection with the VI Business acquisition, the adverse impact from recently enacted tariffs, an increase in logistics and distribution costs and continued cost inflation from macro-economic factors, specifically with respect to labor and raw materials. The decreases in gross margin were partially offset by the net favorable impact of adjustments to our reserves related to the Italian payback measure.

Selling, general and administrative

			Three Months Ended												Nine Months Ended
			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
Selling, general and administrative			$	281.8					$	247.3					$	719.6					$	740.7
Percentage of sales			30.9		%				32.4		%				30.1		%				32.9		%

Selling, general and administrative expenses for the three months ended September 28, 2025 increased $34.5 million compared to the prior year period, which was primarily attributable to $35.2 million in operating costs incurred by the acquired VI Business and amortization of intangible assets recognized in connection with the VI Business acquisition, partially offset by a decrease in sales and marketing expenses related to our legacy businesses.

Selling, general and administrative expenses for the nine months ended September 28, 2025 decreased $21.1 million compared to the prior year period, which was primarily attributable to an $82.2 million benefit from non-designated foreign currency forward contracts designed to hedge against the cash consideration for the VI Business and a decrease in sales and marketing expenses related to our legacy businesses. The decreases in selling, general and administrative expenses were partially offset by $35.2 million in operating costs incurred by the acquired VI Business, amortization of intangible assets recognized in connection with the VI Business acquisition and increases in the estimated fair value of our contingent consideration liabilities.

Research and development

			Three Months Ended												Nine Months Ended
			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
Research and development			$	57.2					$	38.7					$	132.2					$	117.1
Percentage of sales			6.3		%				5.1		%				5.5		%				5.2		%

The increase in research and development expense for the three months ended September 28, 2025 compared to the prior year period, was primarily attributable to expenses incurred by the acquired VI Business.

The increase in research and development expenses for the nine months ended September 28, 2025 compared to the prior year period was primarily attributable to expenses incurred by the acquired VI Business, partially offset by lower European Union Medical Device Regulation related costs.

29

Pension Settlement Charge

									Three Months Ended												Nine Months Ended
															September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
Pension settlement (benefit) charge															$	—					$	(5.4)					$	—					$	132.7

For the nine months ended September 29, 2024, we recognized a settlement charge of $132.7 million related to our plan to terminate the TRIP resulting from our purchase of a group annuity contract to provide participants, beneficiaries, and alternate payees the full value of their benefit under the plan. For the three months ended September 29, 2024, we finalized the premiums owed for the group annuity contract, which resulted in a refund of pension trust assets and a corresponding reduction to the settlement charge of $5.4 million.

Goodwill impairment charge

									Three Months Ended												Nine Months Ended
															September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
Goodwill impairment charge															$	403.9					$	—					$	403.9					$	—

During the three and nine months ended September 29, 2025, we recognized a goodwill impairment charge of $403.9 million related to our IU reporting unit. For additional information, refer to Note 7 within the condensed consolidated financial statements included in this report.

Restructuring charges, separation costs and other impairment charges

			Three Months Ended												Nine Months Ended
			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
Restructuring charges, separation costs and other impairment charges			$	117.6					$	0.3					$	144.6					$	10.8

Restructuring charges, separation costs and impairment charges for the three months ended September 28, 2025 primarily consisted of impairment charges of $100.0 million related to our Titan SGS asset group and $16.0 million of separation costs, primarily consisting of consulting, legal, tax and other professional advisory services associated with the strategic actions.

Restructuring charges, separation costs and impairment charges for the nine months ended September 28, 2025 primarily consisted of impairment charges consisting of $100.0 million related to our Titan SGS asset group and $8.1 million due to our cessation of occupancy at a certain leased facility. In addition, the charges for the nine months ended September 28, 2025 included $32.1 million of separation costs, primarily consisting of consulting, legal, tax and other professional advisory services associated with the strategic actions, and termination charges related to the 2024 Footprint realignment plan.

2023 Footprint realignment plan

In 2023, we initiated the "2023 Footprint realignment plan," a restructuring plan primarily involving the relocation of certain manufacturing operations to existing lower-cost locations, the outsourcing of certain manufacturing processes and related workforce reductions. We estimate that we will incur aggregate pre-tax restructuring and restructuring related charges in connection with the plan of $11 million to $15 million. We expect to achieve annual pretax savings in connection with the 2023 Footprint realignment plan of $2 million to $4 million once the plan is fully implemented.

2024 Restructuring plan

During the fourth quarter of 2024, we initiated the "2024 restructuring plan," which included initiatives to optimize operations, reduce costs and enhance efficiencies across our business lines, including the relocation of select office administrative operations. The plan is substantially complete and as a result, we expect future restructuring expenses associated with the plan to be immaterial.

2024 Footprint realignment plan

During the second quarter of 2024, we initiated the "2024 Footprint realignment plan," encompassing several strategic restructuring initiatives. These initiatives primarily include the relocation of select manufacturing operations to existing lower-cost locations, the optimization of specific product portfolios through targeted rationalization efforts, the relocation of certain integral product development and manufacturing support functions, the optimization of

30

certain supply chain activities and related workforce reductions. The plan is substantially complete and as a result, we expect future restructuring expenses associated with the plan to be immaterial.

VI Business integration plan

During the fourth quarter of 2025, the Board of Directors approved a restructuring plan related to the integration of the VI Business into Teleflex (the “VI Business Integration plan”). The VI Business Integration plan encompasses the realignment of the global sales force and certain administrative functions, including workforce reductions, and the relocation of certain manufacturing operations to existing lower-cost locations. These actions are expected to be substantially completed by the end of 2028. The following table provides a summary of our estimates of restructuring and restructuring related charges by major type of expense associated with the VI Business Integration plan:

VI Business Integration plan

Plan expense estimates:

(Dollars in millions)

Restructuring charges (1)

$26 million to $31 million

Restructuring related charges (2)

$10 million to $13 million

Total restructuring and restructuring related charges

$36 million to $44 million

(1)Substantially all of the charges consist of employee termination benefit costs.

(2)Restructuring related charges represent costs that are directly related to the program and principally constitute costs to transfer manufacturing operations to existing lower-cost locations and project management costs. The majority of these charges are expected to be recognized within cost of goods sold.

We expect all the restructuring and restructuring related charges will result in future cash outlays, of which, an estimated $12 million to $14 million are expected to occur during 2026. Additionally, we expect to incur $5 million to $7 million in aggregate capital expenditures under the VI Business Integration plan, which are expected to be incurred mostly between 2026 and 2027. We expect to achieve annual pre-tax savings of $24 million to $30 million in connection with the VI Business Integration plan once it is fully implemented and we expect to begin realizing plan-related savings in 2026.

For additional information regarding our restructuring plans, refer to Note 5 within the condensed consolidated financial statements included in this report.

Interest expense

			Three Months Ended												Nine Months Ended
			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
Interest expense			$	31.8					$	21.1					$	72.1					$	64.9
Average interest rate on debt			4.1		%				4.5		%				4.1		%				4.5		%

The increases in interest expense for the three and nine months ended September 28, 2025 compared to the prior year periods were primarily due to an increase in the average outstanding debt balance stemming from new borrowings utilized to fund the VI Business acquisition, partially offset by a lower average interest rate resulting from decreases in interest rates associated with our variable interest rate debt instruments.

Taxes on income from continuing operations

			Three Months Ended												Nine Months Ended
			September 28, 2025						September 29, 2024						September 28, 2025						September 29, 2024
Effective income tax rate (1)			6.8		%				15.0		%				1.6		%				(2.3)		%

(1)The effective income tax rates for the three and nine months ended September 28, 2025 and the nine months ended September 29, 2024 represent an income tax benefit. The effective income tax rate for the three months ended September 29, 2024 represents income tax expense.

The effective income tax rates for the three and nine months ended September 28, 2025 reflect a non-deductible goodwill impairment charge related to the IU reporting unit. Additionally, the effective income tax rates for the three and nine months ended September 28, 2025 reflect a tax benefit associated with the impairment of the Titan SGS asset group. The effective income tax rate for the nine months ended September 28, 2025 reflects non-taxable favorable adjustments incurred in relation to foreign currency exchange rates, largely stemming from non-designated foreign currency forward contracts designed to hedge against the cash consideration for the VI Business acquisition. All periods include a tax benefit from research and development tax credits. The effective income tax

31

rate for the nine months ended September 29, 2024 reflects a tax benefit associated with a pension settlement charge recognized in connection with the termination of the TRIP defined benefit plan.

On July 4, 2025, the One Big Beautiful Bill (“OBBB”) Act was signed into law, enacting certain extensions and significant modifications to existing U.S. tax law provisions. While we continue to evaluate its implications, we do not currently expect the OBBB Act to have a material impact on our 2025 results of operations.

Segment Financial Information

Segment net revenues
			Three Months Ended																		Nine Months Ended
			September 28, 2025						September 29, 2024						% Increase/(Decrease)						September 28, 2025						September 29, 2024						% Increase/ (Decrease)
Americas			$	555.9					$	515.9					7.8						$	1,557.3					$	1,525.5					2.1
EMEA			234.2						150.2						55.9						551.6						456.9						20.7
Asia			122.9						98.3						25.0						285.7						269.5						6.0
Segment net revenues			$	913.0					$	764.4					19.4						$	2,394.6					$	2,251.9					6.3
Segment operating profit
			Three Months Ended																		Nine Months Ended
			September 28, 2025						September 29, 2024						% Increase/(Decrease)						September 28, 2025						September 29, 2024						% Increase/ (Decrease)
Americas			$	176.0					$	174.0					1.2						$	501.8					$	496.6					1.0
EMEA			27.6						34.7						(20.4)						101.7						94.1						8.1
Asia			20.5						33.7						(39.1)						61.5						85.6						(28.1)
Segment operating profit (1)			$	224.1					$	242.4					(7.5)						$	665.0					$	676.3					(1.7)

(1)See Note 14 to our condensed consolidated financial statements included in this report for a reconciliation of segment operating profit to our condensed consolidated income from continuing operations before interest and taxes.

Comparison of the three and nine months ended September 28, 2025 and September 29, 2024

Americas

Americas net revenues for the three months ended September 28, 2025 increased $40.0 million, or 7.8%, compared to the prior year period, which was primarily attributable to net revenues of $25.1 million generated by the acquired VI Business and increases in sales volumes of new and existing products, mostly in our Interventional and Surgical product categories.

Americas net revenues for the nine months ended September 28, 2025 increased $31.8 million, or 2.1%, compared to the prior year period, which was primarily attributable to net revenues of $25.1 million generated by the acquired VI Business, a $21.5 million increase in sales of new products and price increases. The increases in net revenues were partially offset by a $24.5 million decrease in sales volumes of existing products, primarily driven by declines in sales related to our OEM product category and UroLift product line.

Americas operating profit for the three months ended September 28, 2025 increased $2.0 million, or 1.2%, compared to the prior year period, which was primarily attributable to an increase in gross profit resulting from higher sales, including revenue generated by the acquired VI Business, partially offset by the adverse impact from the amortization of the step-up in carrying value of inventory and intangible assets recognized in connection with the VI Business acquisition, unfavorable fluctuations in foreign currency exchange rates and higher manufacturing costs. The increases in operating profit were also adversely impacted by increases in operating costs incurred by the acquired VI Business.

Americas operating profit for the nine months ended September 28, 2025 increased $5.2 million, or 1.0%, compared to the prior year period, which was primarily attributable to an increase in gross profit as a result of revenues generated by the acquired VI Business and decreases in sales and marketing expenses related to our legacy businesses, partially offset by the adverse impact from the amortization of the step-up in carrying value of inventory and intangible assets recognized in connection with the VI Business acquisition, increases in operating costs incurred by the acquired VI Business and an increase in contingent consideration expense resulting from changes in the estimated fair value of our contingent consideration liabilities.

32

EMEA

EMEA net revenues for the three months ended September 28, 2025 increased $84.0 million, or 55.9%, compared to the prior year period, which was primarily attributable to net revenues of $50.0 million generated by the acquired VI Business, the favorable impact of a $23.7 million decrease in our reserves related to the Italian payback measure and $9.1 million of favorable fluctuations in foreign currency exchange rates.

EMEA net revenues for the nine months ended September 28, 2025 increased $94.7 million, or 20.7%, compared to the prior year period, which was primarily attributable to net revenues of $50.0 million generated by the acquired VI Business, a $39.5 million net favorable impact from adjustments to our reserves related to the Italian payback measure, which was driven by the $23.7 million favorable adjustment recognized in the current period compared to an unfavorable adjustment of $15.8 million in the prior period, and favorable fluctuations in foreign currency exchange rates. The increases in net revenues were partially offset by a decrease in sales volumes of existing products.

EMEA operating profit for the three months ended September 28, 2025 decreased $7.1 million, or 20.4%, compared to the prior year period, which was primarily attributable to increases in operating costs incurred by the acquired VI Business and the unfavorable impact within gross margin from the amortization of the step-up in carrying value of inventory and intangible assets recognized in connection with the VI Business acquisition. The decreases in operating profit were offset by favorable impacts within gross margin from an increase in revenues generated by the acquired VI Business and a decrease in our reserves related to the Italian payback measure.

EMEA operating profit for the nine months ended September 28, 2025 increased $7.6 million, or 8.1%, compared to the prior year period, which was primarily attributable to an increase in gross profit as a result of an increase in revenues generated by the VI Business Acquisition and the net favorable impact from adjustments in our reserves related to the Italian payback measure, partially offset the adverse impact from the amortization of the step-up in carrying value of inventory and intangible assets recognized in connection with the VI Business acquisition. The increases in operating profit were also impacted by favorable fluctuations in foreign currency exchange rates and an adverse impact from increases in operating costs incurred by the acquired VI Business.

Asia

Asia net revenues for the three months ended September 28, 2025 increased $24.6 million, or 25.0%, compared to the prior year period, which was primarily attributable to net revenues of $26.6 million generated by the acquired VI Business and a $9.4 million favorable impact from a stocking order in China related to recently implemented initiatives intended to expand the sales channel of intra-aortic balloon pumps and catheters. The increases in net revenues were partially offset by a decrease in sales volumes of existing products and price decreases, primarily due to the implementation of volume-based procurement programs in China.

Asia net revenues for the nine months ended September 28, 2025 increased $16.2 million, or 6.0%, compared to the prior year period, which was primarily attributable to net revenues of $26.6 million generated by the acquired VI Business and a $9.4 million favorable impact from a stocking order in China related to recently implemented initiatives intended to expand the sales channel of intra-aortic balloon pumps and catheters. The increases in net revenues were partially offset by an $11.3 million decrease in sales volumes of existing products and price decreases primarily due to the implementation of volume-based procurement programs in China.

Asia operating profit for the three months ended September 28, 2025 decreased $13.2 million, or 39.1%, compared to the prior year period, which was primarily attributable to a decrease in gross profit that was primarily attributed to the adverse impact from the amortization of the step-up in carrying value of inventory and intangible assets recognized in connection with the VI Business acquisition, price decreases and unfavorable product mix, partially offset by gross profit generated from higher sales resulting from the acquired VI Business. The decrease in operating profit was also attributed to increases in operating costs incurred by the acquired VI Business.

Asia operating profit for the nine months ended September 28, 2025 decreased $24.1 million, or 28.1%, compared to the prior year period, which was primarily attributable to a decrease in gross profit that was primarily attributed to the adverse impact from the amortization of the step-up in carrying value of inventory and intangible assets recognized in connection with the VI Business acquisition, price decreases and unfavorable product mix, partially offset by gross profit generated from higher sales resulting from the acquired VI Business. The decrease in operating profit was also impacted by unfavorable fluctuations in foreign currency exchange rates and increases in operating costs incurred by the acquired VI Business.

33

We are currently monitoring increased inventory levels of our intra-aortic balloon pumps and catheters at some of our distributors in China, as we have observed that their sales to third parties have been slower than had been anticipated and in light of the recent stocking order related to our recently implemented initiative to expand the sales channel. If demand for our pumps and catheters does not increase, or our efforts to expand the sales channel are not successful, we could experience an adverse impact on our future results.

Liquidity and Capital Resources

We believe our cash flow from operations, available cash and cash equivalents and borrowings under our revolving credit facility will enable us to fund our operating requirements, including those arising from newly implemented tariffs, capital expenditures, debt obligations and separation costs for the next 12 months and the foreseeable future. We have net cash provided by United States based operating activities as well as non-United States sources of cash available to help fund our debt service requirements in the United States. We manage our worldwide cash requirements by monitoring the funds available among our subsidiaries and determining the extent to which we can access those funds on a cost effective basis.

Concurrent with the execution of the agreement to acquire the VI Business, we entered into foreign exchange derivative contracts with an aggregate notional value of €700 million to hedge economically against the foreign currency exposure associated with the cash consideration needed to complete the VI Business acquisition. These forward contracts were settled on June 30, 2025 concurrent with the completion of our acquisition. The settlement of the forward currency contracts resulted in proceeds of $82.2 million.

On July 30, 2024, the Board of Directors authorized a share repurchase program for up to $500 million of our common stock. On February 28, 2025, we entered into an accelerated share repurchase agreement for $300 million of our common stock, representing the remainder of the share repurchase program approved by the Board of Directors in 2024. Under this agreement, 1,725,253 shares of common stock, representing 80% of the $300 million aggregate, were delivered and included in treasury stock during the three months ended March 30, 2025. The initial shares received were calculated based on a price per share of $139.11, which was the closing share price of our common stock on February 27, 2025. Final settlement under the agreement occurred on April 9, 2025, at which time we received 493,150 additional shares of common stock. The total shares received were calculated based on a price per share of $135.23, which was based on volume-weighted average prices of our common stock during the accelerated share repurchase period less a discount.

On August 18, 2025, we executed two separate term cross-currency swap agreements set to expire on August 20, 2030 and August 20, 2032, respectively, to hedge against the effect of variability in the U.S. dollar to Swiss Franc (CHF) exchange rate, (the "2025 Cross-currency swap agreements"). Each of the 2025 Cross-currency swap agreements had a notional principal amount of $300 million and were designated as a net investment hedge. The 2025 Cross-currency swap agreements expiring in 2030 include six different financial institution counterparties and notionally exchanged $300 million for CHF 242.4 million at an annual interest rate of 3.15%. The 2025 Cross-currency swap agreements expiring in 2032 include four different financial institution counterparties and notionally exchanged $300 million for CHF 242.5 million at an annual interest rate of 3.02%.

In the fourth quarter of 2025, and prior to the original October 4, 2025 maturity date, we terminated the 2023 Cross-currency swap agreements and executed new cross-currency swap agreements with five financial institution counterparties. Under these new cross-currency swap agreements, which mature in March 2026, we notionally exchanged $500 million at an annual interest rate of 4.63% for €474.7 million at an annual interest rate of 2.77%. Further, the zero cost foreign exchange collar contract associated with the 2023 Cross-currency swap agreements matured in October 2025 resulting in an immaterial impact to our financial results.

Cash Flows

Net cash provided by operating activities from continuing operations was $189.0 million for the nine months ended September 28, 2025 as compared to $435.6 million for the nine months ended September 29, 2024. The $246.6 million decrease was primarily attributable to unfavorable changes in working capital and unfavorable operating results. The unfavorable changes in working capital were primarily driven by a net increase in accounts receivable resulting from of an increase in receivables associated with the VI Business (as we did not acquire certain trade receivables) and higher sales; and the prior period inflow from proceeds received from the TRIP termination included within prepaid expenses and other assets. Net cash provided by operating activities from continuing operations was also unfavorably impacted by recently enacted tariffs and higher tax payments.

Net cash used in investing activities from continuing operations was $826.8 million for the nine months ended September 28, 2025, and primarily consisted of $833.2 million in net payments for businesses and intangibles

34

acquired, primarily related to the VI Business acquisition, and $94.6 million of capital expenditures, partially offset by $82.2 million in proceeds from the settlement of foreign currency forward contracts entered to hedge economically against the foreign currency exposure associated with the VI Business acquisition and $9.5 million in insurance settlement proceeds.

Net cash provided by financing activities from continuing operations was $673.1 million for the nine months ended September 28, 2025, and primarily consisted of a $1.0 billion increase in net proceeds from borrowings under our Senior Credit Facility, partially offset by $300.0 million in repurchases of our common stock under the accelerated share repurchase agreement and $45.2 million in dividend payments.

Borrowings

The indentures governing our 4.625% Senior Notes due 2027 (the “2027 Notes”) and 4.25% Senior Notes due 2028 (the "2028 Notes") contain covenants that, among other things and subject to certain exceptions, limit or restrict our ability, and the ability of our subsidiaries, to create liens; consolidate, merge or dispose of certain assets; and enter into sale leaseback transactions. As of September 28, 2025, we were in compliance with these requirements.

The obligations under our senior credit agreement (the "Credit Agreement"), the 2027 Notes and 2028 Notes are guaranteed (subject to certain exceptions) by substantially all of our material domestic subsidiaries, and the obligations under the Credit Agreement are (subject to certain exceptions and limitations) secured by a lien on substantially all of the assets owned by us and each guarantor.

Concurrent with the execution of the agreement to acquire the VI Business, we entered into an amendment to our Third Amended and Restated Credit Agreement (the “Credit Agreement”) on February 24, 2025, which, among other things, (a) provides for a delayed draw term loan facility in an aggregate principal amount of $500 million, to be available to be drawn on the date on which we consummate the VI Business acquisition and (b) permits us to borrow up to $550 million under the revolving facility provided for under the Credit Agreement on a limited condition basis on the date on which the VI Business acquisition is consummated. Borrowings under the delayed draw term loan are to bear interest at a rate per annum equal to the applicable margin plus, at our option, either (1) the highest of (i) the “Prime Rate” in the U.S. last quoted by The Wall Street Journal, (ii) 0.50% above the greater of the federal funds rate and the rate comprised of both overnight federal funds and overnight euro transactions denominated in U.S. dollars and (iii) 1.00% above the Term SOFR Rate for a one month interest period, plus an applicable margin ranging from 0.125% to 1.00%, in each case subject to adjustments based on our total net leverage ratio or (2) a Term Secured Overnight Financing Rate (“SOFR”) rate (which includes a credit spread adjustment of 10 basis points). The applicable margin for borrowings under the delayed draw term loan range from 1.125% to 2.00% for SOFR borrowings and from 0.125% to 1.00% for base-rate borrowings, in each case, depending on, at our election, either (x) our public corporate family rating or (y) our consolidated total net leverage ratio, in each case, based on the most recently ended fiscal quarter. The obligations under the delayed draw term loan will be guaranteed and secured on the same basis as the facilities provided for under the Credit Agreement. The delayed draw term loan will not amortize and will mature on the earlier of (x) the date that is two years after the date on which such loans are funded and (y) the maturity date for the revolving facility provided for under the Credit Agreement.

Subsequently, on June 24, 2025, we executed a further amendment to the Credit Agreement, increasing the aggregate principal amount of the delayed term loan facility by $200 million. After giving effect to the amendment, the delayed draw term loan facility provides for an aggregate amount of delayed draw term loan commitments of $700 million. On June 30, 2025, the first day of the third fiscal quarter of 2025, we drew $700 million under the delayed draw term loan facility in addition to $140 million of borrowings under our revolving credit facility to fund the VI Business acquisition, inclusive of transaction-related costs and other associated requirements.

Summarized Financial Information – Obligor Group

The 2027 Notes are issued by Teleflex Incorporated (the “Parent Company”), and payment of the Parent Company's obligations under the Senior Notes is guaranteed, jointly and severally, by an enumerated group of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. Summarized financial information for the Parent and Guarantor Subsidiaries (collectively, the “Obligor Group”) as of September 28, 2025 and December 31, 2024 and for the nine months ended September 28, 2025 is as follows:

35

						Nine Months Ended
						September 28, 2025
						Obligor Group						Intercompany						Obligor Group (excluding Intercompany)
Net revenue						$	1,648.9					$	239.5					$	1,409.4
Cost of goods sold						1,018.5						196.7						821.8
Gross profit						630.4						42.8						587.6
Income (loss) from continuing operations						88.4						157.4						(69.0)
Net income (loss)						88.3						157.4						(69.1)

						September 28, 2025																		December 31, 2024
						Obligor Group						Intercompany						Obligor Group  (excluding Intercompany)						Obligor Group						Intercompany						Obligor Group  (excluding Intercompany)
Total current assets						$	1,182.5					$	170.8					$	1,011.7					$	1,034.1					$	201.2					$	832.9
Total assets						2,847.2						259.9						2,587.3						2,815.2						277.8						2,537.4
Total current liabilities						1,065.5						669.9						395.6						1,275.4						953.4						322.0
Total liabilities						4,211.5						828.3						3,383.2						3,450.5						1,126.6						2,323.9

The same accounting policies as described in Note 1 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 are used by the Parent Company and each of its subsidiaries in connection with the summarized financial information presented above. The Intercompany column in the table above represents transactions between and among the Obligor Group and non-guarantor subsidiaries (i.e. those subsidiaries of the Parent Company that have not guaranteed payment of the Senior Notes). Obligor investments in non-guarantor subsidiaries and any related activity are excluded from the financial information presented above.

Critical Accounting Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from the amounts derived from those estimates and assumptions.

In our Annual Report on Form 10-K for the year ended December 31, 2024, we provided disclosure regarding our critical accounting estimates, which are reflective of significant judgments and uncertainties, are important to the presentation of our financial condition and results of operations and could potentially result in materially different results under different assumptions and conditions.

New Accounting Standards

See Note 2 to the condensed consolidated financial statements included in this report for a discussion of recently issued accounting guidance, including estimated effects, if any, of the adoption of the guidance on our financial statements.

Forward-Looking Statements

All statements made in this Quarterly Report on Form 10-Q, other than statements of historical fact, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “will,” “would,” “should,” “guidance,” “potential,” “continue,” “project,” “forecast,” “confident,” “prospects” and similar expressions typically are used to identify forward-looking statements. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about our business and the industry and markets in which we operate. These statements are not guarantees of future performance and are subject to risks and uncertainties, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements due to a number of factors, including changes in business relationships with and purchases by or from major customers or suppliers; delays or cancellations in shipments; demand for and market acceptance of new and existing products; the impact of inflation and disruptions in our global supply chain on us and our suppliers (particularly sole-source suppliers and providers of sterilization services), including fluctuations in the cost and availability of resins and other raw materials, as well as certain

36

components, used in the production or sterilization of our products, transportation constraints and delays, product shortages, energy shortages or increased energy costs, labor shortages in the United States and elsewhere, and increased operating and labor costs; our inability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with our expectations; our inability to effectively execute our restructuring programs; our inability to realize anticipated savings resulting from restructuring plans and programs; the impact of enacted healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, the implementation or threatened implementation of tariffs, sovereign debt issues, and international conflicts and hostilities, such as the ongoing conflicts between Russia and Ukraine and in the Middle East; public health epidemics and pandemics, such as COVID-19; difficulties entering new markets; and general economic conditions. For a further discussion of the risks relating to our business, see Item 1A, Risk Factors, in our Annual Report on Form 10-K for the year ended December 31, 2024. We expressly disclaim any obligation to update these forward-looking statements, except as otherwise explicitly stated by us or as required by law or regulation.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes to the information set forth in Part II, Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2024.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are functioning effectively to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Management’s assessment of disclosure controls and procedures excluded consideration of the VI Business’ internal control over financial reporting. The VI Business was acquired during the third quarter of 2025, and the exclusion is consistent with guidance provided by the staff of the Securities and Exchange Commission that an assessment of a recently acquired business may be omitted from management’s report on internal control over financial reporting for up to one year from the date of acquisition, subject to specified conditions. The VI Business’ total assets represent 13% of our consolidated total assets as of September 28, 2025; and its net revenues represented 4% of our consolidated net revenues for the nine months ended September 28, 2025.

(b) Change in Internal Control over Financial Reporting

As a result of our acquisition of the VI Business, we are in the process of evaluating the VI Business’ internal controls to determine the extent to which modifications to the VI Business' internal controls would be appropriate. As we continue to integrate the acquired operations of the VI Business, we have extended our oversight and monitoring processes that support our internal control over financial reporting, as well as our disclosure controls and procedures, to the VI Business. There were no other changes in our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

37

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

We are party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability and product warranty, intellectual property, contracts, employment and environmental matters. As of September 28, 2025 and December 31, 2024, we had accrued liabilities of $1.9 million and $0.8 million in connection with these matters, representing our best estimate of the cost within the range of estimated possible loss that will be incurred to resolve these matters. Amounts accrued for legal contingencies are often determined based on a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions, including as to the timing of related payments. The ability to make such estimates and judgments can be affected by various factors including whether, among other things, damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has commenced or is complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute, or procedural or jurisdictional issues; there is uncertainty or unpredictability regarding the number of potential claims; there is the potential to achieve comprehensive multi-party settlements; there is complexity regarding related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against us, we do not record an accrual until a loss is determined to be probable and can be reasonably estimated.

Based on information currently available, advice of counsel, established reserves and other resources, we do not believe that any such actions are likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or cash flows. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or cash flows.

Item 1A. Risk Factors

See the information set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024. There have been no significant changes in risk factors for the quarter ended September 28, 2025.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Rule 10b5-1 Trading Plans

During the third quarter of 2025, none of our directors or executive officers entered into, modified or terminated, (i) any contracts, instructions or written plans for the sale of purchase of our securities that were intended to satisfy the affirmative defense conditions of Rule 10b5-1, or (ii) any non-Rule 10b5-1 trading arrangement, as defined in Item 408(a) of Regulation S-K.

Legal Settlement

On March 6, 2025, a putative class action complaint captioned Harrison v. Teleflex Incorporated, et al., C.A. No. 2025-0251-JTL (Del. Ch.) was filed in the Court of Chancery of the State of Delaware (the “Court”) against us and our Board (the “Action”). The plaintiff alleged in the complaint that a provision in our Bylaws restricting stockholders’ ability to act by written consent violated the Delaware General Corporation Law. Pursuant to a stipulation and proposed order, which the Court entered on April 7, 2025, the individual defendants were dismissed from the Action, leaving us as the sole defendant. On May 15, 2025, we filed a Form 8-K with the SEC stating that we had amended our Bylaws to remove the challenged provision on May 9, 2025. Thereafter, the parties agreed that the amendment

38

mooted the claims in the Action and filed a Stipulation and Proposed Order dismissing the Action with prejudice as to the plaintiff in the Action only. Without admitting any fault or wrongdoing, we agreed to pay a mootness fee to plaintiff’s counsel in the Action in the amount of $55,000 (the "Mootness Fee"). On August 5, 2025, the Court entered a proposed order dismissing the Action as moot, subject to our filing an affidavit with the Court confirming compliance with the requirement in the order that we disclose in its next periodic filing with the SEC the payment of the Mootness Fee. In entering the order, the Court did not review, and did not pass judgment, on the payment of these attorneys’ fees and expenses. As a result, we have no further potential liability related to this matter.

39

Item 6. Exhibits

The following exhibits are filed as part of, or incorporated by reference into, this report:

 

Exhibit No.												Description
*10.1						—						Amendment No. 2 to Credit Agreement, dated as of June 24, 2025, among Teleflex Incorporated, each subsidiary of Teleflex Incorporated party thereto, each lender party thereto and JPMorgan Chase Bank, N.A., as administrative agent (incorporated by reference to Exhibit 10.1 to the Company's Form 8-K filed on June 30, 2025).
*22						—						List of subsidiary guarantors and guaranteed securities (incorporated by reference to Exhibit 22 to the Company's Form 10-K filed on February 28, 2025).
31.1						—						Certification of Chief Executive Officer, pursuant to Rule 13a–14(a) under the Securities Exchange Act of 1934.
31.2						—						Certification of Chief Financial Officer, pursuant to Rule 13a–14(a) under the Securities Exchange Act of 1934.
32.1						—						Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2						—						Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.1						—						The following materials from our Quarterly Report on Form 10-Q for the quarter ended September 28, 2025, formatted in inline XBRL (eXtensible Business Reporting Language): (i) Cover Page; (ii) the Condensed Consolidated Statements of Income for the three and nine months ended September 28, 2025 and September 29, 2024; (iii) the Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 28, 2025 and September 29, 2024; (iv) the Condensed Consolidated Balance Sheets as of September 28, 2025 and December 31, 2024; (v) the Condensed Consolidated Statements of Cash Flows for the nine months ended September 28, 2025 and September 29, 2024; (vi) the Condensed Consolidated Statements of Changes in Equity for the three and nine months ended September 28, 2025 and September 29, 2024; and (vii) Notes to Condensed Consolidated Financial Statements.
104.1						—						The cover page of the Company's Quarterly Report on Form 10-Q for the quarter ended September 28, 2025, formatted in inline XBRL (included in Exhibit 101.1).

____________________________________

*Incorporated by reference.

40

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TELEFLEX INCORPORATED

By:

/s/ Liam J. Kelly

Liam J. Kelly President and Chief Executive Officer (Principal Executive Officer)

By:

/s/ John R. Deren

John R. Deren Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)

Dated: November 6, 2025

41

FAQ

What were Teleflex (TFX) Q3 2025 revenues and earnings?

Q3 net revenues were $913,021. The company reported a net loss of $(408,892), impacted by impairments and restructuring-related costs.

What impairments did Teleflex record in Q3 2025?

Teleflex recognized a $403,925 goodwill impairment in Interventional Urology and a $100,000 impairment related to Titan SGS.

What is the status and cost of the BIOTRONIK Vascular Intervention acquisition?

Closed on June 30, 2025 for €704.3 million ($825.2 million), financed with a $700 million delayed draw term loan and revolver borrowings.

How did the acquisition affect Teleflex’s debt?

Total borrowings rose to $2,681,250, including the new delayed draw term loan and higher revolver usage.

What were year-to-date cash flows for 2025?

Operating cash flow: $188,971. Investing cash flow: $(826,782) (driven by the acquisition). Financing cash flow: $673,148.

What are Teleflex’s plans for a separation?

The company is pursuing a separation of NewCo and recorded $32,144 in year‑to‑date separation costs. Completion remains subject to approvals.

How many Teleflex shares are outstanding?

There were 44,194,408 shares outstanding as of November 4, 2025.